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Abstract 
Background: Osteosarcoma (OS) is the most common malignant primary bone tumor that appears 
in childhood and adolescence. It was recently demonstrated that OS possesses a small population 
with stem-like features, CSCs, which are responsible for the heterogeneity and regenerative ability 
of tumor cells and are considered responsible for the resistance to conventional therapies, namely 
chemotherapy and radiotherapy.  Metformin (METF) is one of the most prescribed drugs to treat 
type II diabetes and in the past decade METF gained special attention in cancer treatment because 
of its anticancer properties. In this study we propose to explore the potential role of METF as an 
adjuvant of doxorubicin (DOX) to target CSCs from OS, exploring the effects and signaling 
pathways underlying the anticancer properties of metformin on OS CSCs. 
Methods: CSCs were isolated from two human OS cell lines MNNG/HOS and MG-63 through the 
sphere–forming assay and then characterized regarding the expression of stem cell-specific 
transcription factors by immunofluorescence. The effects of MEFT on cell viability and 
proliferation was evaluated using the MTT and BrdU assays, respectively, and on sphere formation 
and self-renewal of CSCs. We also studied the chemosensitizing properties of METF on DOX 
cytotoxicity in both parental and corresponding CSCs. The metabolic state of cells following 
exposure to METF was assessed based on [18F]FDG uptake. The phosphorylated form of AMPK, 
which is the main target of METF and of mTOR were analysed by Western blot.  
Results: Both human OS cell lines MNNG/HOS and MG-63 contain sphere-forming cell subsets 
with stem-like properties expressing Oct4 and Nanog pluripotency markers, which are relatively 
more resistant to DOX than their differentiated counterparts. METF reduced the proliferation rate 
and viability of both cell types but was preferentially cytotoxic to CSCs relative to parental cells in 
a dose-dependent manner, and decreased the sphere-forming and self-renewal ability of both 
CSCs populations. Moreover, METF potentiate the cytotoxic effects of DOX in both cell 
populations, although the chemosensitizing effect has been more pronounced against CSCs. METF 
stimulates [18F]FDG uptake in parental differentiated cells but not in CSCs. Exposure to METF 
induced dose-dependent increase in AMPK activation, with a more pronounced effect in CSCs. 
Conclusion: MEFT demonstrated a preferential cytotoxicity against CSCs relatively to 
corresponding parental cells and inhibit the sphere-forming and self-renewal of CSCs. METF 
induce activation of AMPK and potentiates the cytotoxic effects of DOX mainly in CSCs. Collectively 
xvi 
 
our results suggest that METF combined with DOX may be an effective treatment strategy for 
targeting CSCs in OS. 
Keywords: osteosarcoma; cancer stem cells; metformin; doxorubicin; co-adjuvant 
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Resumo 
Introdução: Osteossarcoma (OS) representa o tumor ósseo primário mais comum aparecendo 
frequentemente na infância e adolescência. Recentemente foi demonstrada a presença de uma 
população com características de células estaminais em OS, as células estaminais cancerígenas 
(CSCs), que são consideradas responsáveis pela heterogeneidade e capacidade regenerativa das 
células tumorais. Para além disso, são também responsáveis pela resistência a terapias 
convencionais, como quimioterapia e radioterapia. Metformina (METF) é um dos fármacos mais 
prescritos no tratamento da diabetes tipo II. Na última década tem ganho especial atenção no 
tratamento contra o cancro devido às suas propriedades anticancerígenas. Neste estudo foi 
proposto explorar o papel da METF como adjuvante da doxorrubicina (DOX) tendo como alvo as 
CSCs de OS, para tal analisámos os efeitos e as vias de sinalização subjacentes às propriedades 
anticancerígenas da METF nestas CSCs. 
Métodos: As CSCs foram isoladas a partir das linhas humanas de OS MNNG/HOS e MG-63 pelo 
método de formação de esferas e posteriormente caracterizadas tendo em conta a expressão de 
fatores de transcrição específicos de células estaminais, por imunofluorescência. Os efeitos da 
METF na viabilidade e proliferação celulares foi avaliada através dos ensaios de MTT e BrdU, 
respetivamente, e na formação de esferas e auto-renovação das CSCs. Também foi analisado o 
efeito “chemosensitizing” da METF na citotoxicidade da DOX em CSCs assim como em ambas as 
linhas parentais. O estado metabólico das células após tratamento com METF parentais foi 
permitido pela análise de captação de [18F]FDG. A forma fosforilada de AMPK, que representa o 
principal alvo da METF e o mTOR foram analisados por Western Blot. 
Resultados: Ambas as linhas celulares de OS MNNG/HOS e MG-63 contém uma subpopulação de 
células com características de células estaminais que expressam marcadores de pluripotência, 
Oct4 e Nanog. METF, as quais sais são relativamente mais resistentes à DOX do que as células 
parentais. A METF reduziu a taxa de proliferação e viabilidade em ambos os tipos celulares mas 
foi preferencialmente citotóxico para as CSCs, sendo este efeito dependente da dose. Também 
diminuiu a capacidade de formação de esferas e a sua capacidade de auto-renovação. Para além 
disso, a METF potenciou o efeito citotóxico da DOX em ambas as populações celulares, embora 
esse efeito tenha sido mais pronunciado nas CSCs. METF aumentou a captação de [18F]FDG nas 
células parentais diferenciadas mas não nas CSCs. Exposição à METF induziu um aumento 
dependente da dose na ativação de AMPK, com um efeito mais pronunciado nas CSCs. 
xviii 
 
Conclusão: A METF demonstrou uma citotoxicidade preferencial para as CSCs relativamente às 
células parentais para além de que diminuiu a formação de esferas e a sua capacidade de auto-
renovação. METF induziu a ativação de AMPK e potenciou os efeitos citotóxicos de DOX, 
principalmente nas CSCs. Em conjunto, os nossos resultados sugerem que o tratamento 
combinado de METF e DOX, pode ser uma abordagem eficaz na eliminação de CSCs no OS. 
 
Palavras-Chave: Osteossarcoma; células estaminais cancerígenas; metformina; doxorrubicina; 
adjuvante 
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1.1. Osteosarcoma 
1.1.1 Epidemiology 
Osteosarcoma (OS) is the most common malignant primary bone tumor that appears in 
childhood and adolescence, comprising 20% of all bone tumors and 5% of pediatric tumors 
overall. It represents the sixth most common cause of cancer in > 15 years old children, and is 
considered an aggressive neoplasia. According to epidemiological studies in United States 
(US), it is a relatively rare bone tumor with approximately 400 new cases each year [1]. 
OS affects more males than females with a ratio of 1.6:1.The peak of incidence in females 
is earlier than in males due to the earlier onset of growth support. This disease appears 
frequently during puberty, where the growth support is highest, suggesting that the incidence 
of OS must be correlated with faster growing bone rate in puberty. Furthermore, several 
studies show that young OS patients at a growing age were taller than the normal population 
with the same age peak [2]. 
This tumor has a bimodal age distribution with a peak incidence of OS identified in young 
adults and the second peak of incidence identified in elderly adults. In the latter case, it is 
associated with Paget’s disease of the bone, characterised by an abnormal bone remodelling, 
or as a consequence of treatment for a different cancer [3, 4]. 
OS was reported to occur in all bones of the body; however, it is most frequent in the lower 
long bones, arising at sites of rapid bone growth, such as distal femur (40%), proximal tibia 
(20%) and proximal humerus (10%). OS can also occur in axial skeleton, less than 10% of cases 
in the pediatric age group, most commonly in pelvis. OS grows radially forming a mass; when 
it penetrates the bone cortex it compresses the surrounding soft tissues. This pressure forms 
a pseudocapsular layer, which is referred to as “reactive zone”, as we can see in Figure 1.1 [5, 
7]. 
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Figure 1.1. Osteosarcoma: Osteosarcoma grows radially forming a pseudocapsular layer consider as “reactive 
zone”. Microscopic extensions can also appear and are referred to as satellite lesions. (Adapted from Wittig et al., 
2002) 
 
 
1.1.2 Etiology 
The etiology of this neoplasia is currently unknown; however, some genetic alterations have 
correlated with OS disease. OS is characterised by extensive and heterogeneous genetic 
complexity, which is reflected by the high level of genomic existing alterations [8]. 
Retinoblastoma tumor suppressor gene (RB1), located on chromosome 13, has a main role 
in the pathogenesis of OS. Genetic alterations in RB1 increase approximately 1000 times the 
incidence of OS. If a child has alterations in RB1, the most frequent second tumor is OS, 
increasing 500 times more the risk of developing OS when compared with healthy population. 
Genetic analyses of tumor cells of OS show that 70% of the patients have homozygous loss 
of the RB gene and/or an alteration in RB gene production. The product of RB gene is a nuclear 
phosphoprotein (pRB) involved in the cell cycle control. During G1/S transition, it binds to E2F 
factors resulting in its activation and promotion of DNA synthesis and G1 to S transition [2, 9]. 
Furthermore, genetic alterations on p53 tumor suppressor gene (TP53) have also been 
related with OS occurrence. Activation of p53 gene induce cellular programmes including cell 
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cycle arrest, apoptosis or senescence that avoid accumulation of genetically altered cells. 
Moreover, p53 also play a role in angiogenesis, invasion and motility, glycolysis and 
autophagy. These findings suggest that p53 controls a variety of cellular genes network 
leading to the prevention of cancer development [8, 9]. Some studies show that OS appears 
spontaneously with high prevalence in mice which have heterozygous or homozygous 
mutation in the p53 gene. Also, the OS cell lines manifest p53 loss-of-function mutation that 
leads to lack of terminal differentiation of the osteogenic lineage. These findings support the 
hypothesis that OS occurs associated with a variety of mutations and a growth stimulus [11]. 
Also amplification and over-expression of murine double minute 2 (MDM2) and cyclin-
dependent kinase (CDK4) have been seen in OS patients, suggesting that these genes are 
involved in OS pathogenesis. The MDM2 binds to p53 and sequesters it in the nucleolus, 
preventing the inactivation of p53 by the action of p14 protein; CDK4 gene product forms a 
complex with cyclin D1 (CCND1) which phosphorylates and inactivates the pRB, impairing the 
cell cycle regulation.  Moreover, C-myc and C-fos proto-oncogenes are important in the 
regulation of cell growth and have been found to be amplified or over-expressed in OS cells. 
C-myc product is involved in regulating cell growth and DNA replication, and C-fos regulates 
genes involved in cell growth, differentiation, transformation and bone metabolism [2, 9].  
In similarity with the previously mentioned genetic alterations the Wnt/-catenin, 
Transforming Growth Factor- β (TGFβ), Sonic Hedgehog (Shh) and Delta-Notch signaling 
pathways, which are involved in cellular survival and proliferation, can appear unregulated in 
tumors, as in human OS [9, 12]. 
Other predisposing factors that could lead to the OS pathogenesis include exposure to 
ionizing radiation and Paget’s disease. OS derived from exposure to ionizing radiation is rare 
and occurs after a long period of time and is mainly associated with a higher incidence of OS 
in adult [1]. 
 
 
1.1.3 Pathology and Origin of OS 
The cell of origin of OS has been subject to intensive investigation but it is not completely 
clarified. The bone is a reservoir of growth factors and adult stem/progenitor cells and is also 
an organ with regeneration capacity. OS arises commonly near the growth plates of 
adolescents, the region with the most rapid skeletal growth, in which bone progenitor cells 
are actively in expansion, proliferation and differentiation. Hence, these cells have the 
support to develop malignant phenotypes [13]. 
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Increasing evidence suggest that OS arise from mesenchymal stem cells (MSCs) or 
osteoprogenitor cells caused by genetic and/or epigenetic disruption that occurs during the 
osteoblast differentiation pathway, being characterized by the production of osteoid, an 
amorphous mineralized extracellular matrix lacking the characteristics of mature bone. 
Therefore OS has been regarded as a differentiation disease that results from any disruption 
occurring along the differentiation of MSCs into osteoblasts. MSCs are non-hematopoietic 
multipotent stem cells first discovered in adult bone marrow, although they can be found in 
adipose tissue and umbilical cord blood [9, 14]. These cells display self-renewal ability and 
multilineage differentiation potential along mesenchymal lineages including osteoblasts, 
chondroblasts and adypocytes, but also in cells of non-mesenchymal lineage (myocytes, 
cardiomyocytes, fibroblasts)(Figure 1.2) [4, 15]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Differentiation of MSCs and progression of the osteoblastic lineage: MSCs can differentiate into 
nonhaematopoietic cell types, such as chondrocytes, myoblasts, adipocytes and osteoblasts. (Adapted from Basu-
Roy et al., 2012) 
 
At diagnosis, 80% of OS is localized in one bone site and 20% of those cases have present 
lung metastasis. The lung is the most common site of metastasis, followed by bone. This type 
of pulmonary lesions are responsible for high mortality in OS patients. 
The typical symptoms present in OS patients include pain and swelling that manifest after 
trauma or vigorous physical exercise. It appears later as a hard consistency mass and 
limitations in the join movement, also pathologic fractures may occur [2, 7, 24]. 
In order to confirm these symptoms radiological studies can be performed such as X-rays, 
magnetic resonance imaging (MRI) and computed tomography (CT) to study the extension of 
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the tumor and the involvement of surrounding structures (vessels, nerves, soft tissue); to 
check or determine the sites of metastatic disease and the intraosseous extent of the tumor 
can be performed a bone scintigraphy. The diagnosis is confirmed by histological examination 
of tumor obtained through an incisional or needle biopsy [2, 7]. Moreover, biochemical 
studies show an increase in alkaline phosphatase and also an increase in lactic de-
hydrogenase, these could be related with tumor volume and prognosis. Other prognostic 
indicators include extent of disease at diagnosis, size and location of the tumor, response to 
chemotherapy and surgical remission [9]. 
OS cells have similarities with osteoblast which are characterised as tumors that produce 
osteoid and can be classified in different subtypes of osteosarcoma depending on clinical, 
radiological and histological features [14, 17]. According to the World Health Organization 
(WHO), OS is histologically classified in three major subtypes: osteoblastic, the most common 
(70%), fibroblastic and chondroblastic (10% each), depending on the predominant type of 
matrix within the tumor (osteoid, fibrous or chondroid). Other less frequent types of OS are 
the telangiectatic, small cell, parosteal, periosteal, high-grade surface and secondary 
osteosarcoma [9, 24]. 
OS is considered a clinically and molecularly heterogeneous group of malignancies 
characterised by varying degrees of mesenchymal differentiation. In order to access this, we 
must underlie the alterations that occur in differentiation pathway and the stage of MSCs 
differentiation. Hence, studies of Cdnk2/p16 expression mRNA, which is the key regulator of 
MSC malignant transformation, can help us understand what can be affected in osteoblastic 
differentiation pathway. Loss of Cdkn2, in a later stage, is an important alteration which leads 
to MSC malignant transformation. This suggests that the MSCs give rise to osteogenic tumors 
after malignant transformation. Mohseny and collaborators (2009) confirmed this idea 
through in vitro and in vivo studies, where the loss of Cdkn2 locus is recurrent with 
consequent OS formation. Therefore, alterations in osteoblastic differentiation pathway 
cause production of osteoid (defective and immature) and/or bone tumor cells and there is 
highly proliferative malignant MSCs [9, 16]. Furthermore, it is believed that defects in the 
early stages of osteoblast differentiation pathway lead to the development of more 
aggressive and undifferentiated OS, as we can see in Figure 1.3 [9]. 
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Figure 1.3. Osteosarcoma formation: Defects on osteogenic differentiation can lead to OS development. The 
genetic and epigenetic alterations can occur at different stages of osteogenic differentiation leading to the 
development of more aggressive and undifferentiated OS. (Adapted from Tang et al., 2008) 
 
1.1.4 Therapeutic approach 
Before the 1970s the use of effective chemotherapy was not successfully established which 
lead to a poor outcome for patients with OS, with 2-year overall survival rates of 15%-20% 
following surgical resection and/or radiotherapy. 80% to 90% of those patients developed 
metastatic recurrence.  
Over the past three decades, the introduction of high-dose multiagent neoadjuvant 
chemotherapy  followed by surgical resection and adjuvant chemotherapy lead to a 
significant improvement in survival rates to approximately 65%-75% in patients without 
clinical evidence of metastatic disease at diagnosis [6, 18, 19]. 
Non-metastatic OS treatment regimens include pre-operative and post-operative 
chemotherapy. The goal of pre-operative or neoadjuvant chemotherapy is the reduction of 
tumor burden and the eradication of micrometastasis. The histological response to pre-
operative chemotherapy, based on the % of tumor necrosis (based on the Huvos grade) has 
proven to be a prognostic factor for the clinical outcome of OS patients. Patients that present 
>90% of tumor necrosis are considered good responders and have a good prognostic with 
reported 5-year survival rate of 65%-75%. On the other hand, patients with < 90% tumor 
necrosis following therapy are considered poor responders and have a worse prognostic [1, 
20, 21]. Despite the great improvement in survival rates with the introduction of multimodal 
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therapy, 20%-40% of patients with non-metastatic OS at diagnosis still relapse and die, mostly 
related with the development of resistance to this current treatment [14, 22]. 
However, some studies showed that an intensification of chemotherapy regimens can lead 
to the improvement of histological response but did not translate into a survival benefit [20, 
23]. 
Presently, accordingly with European and American Osteosarcoma Group Study 
(EURAMOS-1) the most common protocols of chemotherapy applied are the administration 
of Doxorubicin (DOX), Cisplatin (CIS) and a high-dose of Methotrexate (MTX) [2, 24, 25]. 
Doxorubicin (DOX), also known as Adriamycin, is an anthracycline antibiotic with strong 
antitumor activity against a wide number of tumors including breast, ovary, lung, liver and 
stomach cancers, Hodgkin’s lymphoma and others [7, 26].  
DOX acts by binding to DNA-associated enzymes, it can intercalate the base pairs of the 
DNA’s double helix. By its binding to topoisomerase I and II, a variety of cytotoxic effects 
occur in addition to antiproliferation, resulting in DNA damage. Thus, the main mechanism of 
action of DOX appears to be the poisoning of topoisomerase II that results in double-strand 
DNA breaks, resulting in apoptosis. Furthermore, it has been demonstrated that DOX also 
forms adducts with DNA and these lesions are more cytotoxic than those induced by 
topoisomerase II impairment. Adducts are formed at 5’-CG-3’ sites in DNA where the DNA 
sugar group is covalently linked to N2-amino group of guanine. The apoptosis pathway is 
triggered when the attempt to repair the breaks in DNA fail and cellular growth is inhibited 
at phases G1 and G2. Moreover, DOX can intercalate itself into the DNA, with the inhibition of 
both DNA and RNA polymerase, ceasing DNA replication and RNA transcription [27, 28]. This 
anticancer drug has a limited application due to its potential cardiotoxicity that provokes 
cardiomyopathy. Furthermore, DOX also can cause indirect toxicity in the brain and some 
patients present liver injuries [26, 27]. 
CIS, has a central role in cancer chemotherapy, mainly in testicular cancer [29], but can also 
be used in many others cancers, such as ovarian, cervical, head and neck, non-small-cell lung 
cancer [30] and in OS [31]. 
The main action of CIS occurs when it is activated by aquation and subsequently covalently 
binds to DNA forming DNA adducts. These adducts cause distortions in DNA and are 
recognized by several cellular proteins interfering with several signal-transduction pathways 
that provoke apoptotic cell death. Adducts formed by CIS and DNA can also avoid replication 
and transcription leading to the denaturation of DNA double helix [7, 30]. CIS also presents 
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several side effects, such as nephrotoxicity, peripheral neuropathy and ototoxicity, limiting 
the application of this anticancer agent [7, 18, 29]. 
MTX is another chemotherapeutic agent widely used in the treatment of several 
malignancies, namely breast, head and neck, bladder cancers, OS and non-Hodgkin 
lymphoma [33, 34]. MTX is an antifolate that blocks the folate-dependent enzyme 
dihydrofolate reductase (DHFR). This enzyme catalyses the conversion of dihydrofolate (DHF) 
to tetrahydrofolate (THF). DHFR is necessary for maintaining the intracellular pool of THF and 
its derivatives are essential cofactors in one-carbon metabolism. Furthermore, DHFR is 
pivotal in providing purines, pyrimidine and thymidines precursors for the biosynthesis of 
DNA, RNA and amino acids. Inhibition of DHFR through MTX reduces the folate pools 
necessary for the formation of purine and thymidine leading to the disruption of DNA 
replication [35]. Likely other chemotherapeutic agents MTX has secondary effects, provoking 
mainly renal failure accompanied by gastrointestinal, hematological and hepatic dysfunction 
[7, 33]. 
Ifosfamide (IFO) can also be applied in the treatment of OS [31]. This agent causes cross-
linking of DNA strands, inhibiting the synthesis of DNA and proteins. This drug also presents 
toxicity leading to haemorrhagic cystitis and renal failure [7]. However, the combination of 
IFO and the chemotherapeutic agents used does not lead to an improvement in the survival 
rate [31].   
 
1.2 The Cancer Stem Cell Hypothesis 
OS, like other bone sarcomas is characterised by marked clinical, histological and molecular 
heterogeneity [36]. A significant functional and morphological heterogeneity can also exist 
within tumor cells comprising the tumor with significant implications in response to therapy 
[37]. Several factors can contribute to this phenotypic and functional heterogeneity, including 
genetic mutations, epigenetic changes, interactions between the tumor and the 
microenvironment [38]. 
Two models have been proposed to explain the tumor heterogeneity: the clonal evolution 
or stochastic model and the cancer stem cell (CSC) model. The clonal evolution model 
postulates that mutant tumor cells with growth advantages are selected and expanded and 
that all cells within this dominant population have equal capacity to regenerate the tumor. 
Furthermore, clonal evolution also provides the basis to understand the genetic mechanism 
of therapy resistance that can be acquired by cancer cells 37, 39. During the last few years, 
the phenotypic and functional heterogeneity characteristics of solid tumors have been 
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subject of intense research and the CSCs theory emerged as a model to establish the 
heterogeneity and regenerative ability of tumor cells.  
Accordingly to the CSCs hypothesis, tumors are hierarchically organized, such that only a 
small subset of cells with stem-like properties, which represents a reservoir of self-sustaining 
cells with the ability to self-renew, is responsible for sustaining tumorigenesis and 
establishing the cellular heterogeneity inherent in the primary tumor. These self-sustaining 
cells reside at the apex of the developmental pathway and were named as cancer stem cells, 
sharing some characteristics with normal stem cells [40, 41]. These two models are 
represented in Figure 1.4. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Tumor Heterogeneity Models: (A) In the nonhierarchical model mutations arising in tumor cells can 
confer to them a selective growth advantage. (B) Accordingly to the CSC model, tumors are hierarchically 
organized and sustained by a subset of cells with stem cell properties. These cells have the ability to generate 
heterogeneity through differentiation and maintain the tumorigenesis by self-renewal. (Adapted from Visvader 
et al., 2012) 
 
The CSCs have three distinct properties: the selective capacity to initiate tumors and drive 
neoplastic proliferation; the ability to create unlimited copies of themselves by self-renewal, 
and the potential to form mature non-stem cell cancer progeny by differentiation process 
[37, 38, 42]. These cells can divide asymmetrically leading to the formation of an identical 
daughter cell and a more differentiated cell, which, on subsequent divisions, creates the 
majority of tumor bulk, as described in Figure 1.5. The exact origin of CSCs is not completely 
clarified. It is hypothesized that these CSCs may arise through malignant transformation in 
normal stem cells or progenitor cells or in differentiated cells. Once these stem cells are more 
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susceptible to accumulate genetic mutations due to their long life span when compared to 
more differentiated cells, this is postulated. Furthermore, mutations can occur in 
differentiated cells that acquire the properties of stem cells and developed the capacity to 
undergo self-renew [42-44]. 
 
  
 
 
 
 
 
 
 
 
 
Figure 1.5. Cancer stem cells: Cancer stem cells can arise by mutations in normal stem cells or in progenitor cells, 
and subsequently undergo several divisions and differentiate to create primary tumor bulk. (Adapted from Jordan 
et al., 2007) 
 
1.2.1 Methods of identification of CSCs 
The first evidence of the existence of CSCs subpopulation in tumors, also termed tumor-
initiating cells (TIC), arise from studies on acute myeloid leukemia (AML) in 1994 [45]. Bonnet 
and Dick (1997) identified a small subset of cells with stem-like properties, based on the 
CD34+CD38− cell surface phenotype, comprising 0.01-1% of the total population that induced 
leukemia, similarly to the primary tumor when transplanted into immunodeficient mice 
confirming their tumorigenic ability. The generation of leukaemia-like tumors was observed 
by serial transplantation into secondary immunodeficient mice, demonstrating the self-
renewal potential of such cells and their ability to re-establish the phenotypic heterogeneity 
existing in the original tumor [45, 46]. 
Since then, CSCs have been isolated from several types of solid tumors, including breast, 
lung, colon, pancreas, liver, brain and OS [19, 47-52]. 
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Several approaches, including functional assays and evaluation of immunophenotype have 
been explored to identify and isolate CSCs from both hematologic and solid tumors. However, 
any single method is capable of yielding a pure population of stem-like cells [42]. 
A panel of cell surface markers either singly or in combination have been used to identify 
CSCs in several tumors. This panel includes among others CD133, CD44, CD24, epithelial cell 
adhesion molecule (EpCAM), ATP-binding cassette B5 andABCG2. Nevertheless, even with a 
wide range of markers used to discern CSCs, none of these markers are exclusively expressed 
in CSCs of solid tumors, which emphasize the importance of establishing more specific 
markers, improving the knowledge of these markers for every tissue type [14, 54]. 
The CD133/AC133 (prominin-1) antigen is a pentaspan membrane glycoprotein, initially 
identified in neuroepithelial stem cells. CD133 was found to be expressed in cancer initiating 
cells in brain tumors, hepatocarcinoma, breast, pancreatic, lung and colon carcinomas and in 
OS and melanoma being considered a cancer stem cell marker. A population of CD133+ cells 
in brain tumors, but not CD133-, had the ability to grow under anchorage-independent 
conditions, formed tumors in immunocompromised mice, and exhibit stem-like features, 
such as differentiation ability, high proliferation rate and resistance to therapy [55, 56]. 
CD24 and CD44 have been proposed as markers for CSCs in several tumors. However, while 
some literature data referred to the existence of a population of cells with the CD44+/CD24-
phenotype and with stem cell characteristics in breast, prostate, colon, pancreatic and 
hepatic carcinoma, and also in melanoma [57], other literature data demonstrated that a 
subpopulation of CD24+ cells could possess stem cell characteristics in colon and pancreatic 
tumors [58, 59], showed that the lack of CD24 is not an essential feature of CSC [56]. 
ABCG2 is a member of the ABC superfamily of transporters, which pump a variety of 
endogenous and exogenous compounds out of cells. It is recognized as a marker of stem cells 
and plays an important role in promoting stem cells proliferation and in the maintenance of 
its phenotype [60]. The overexpression of ABCG2 in CSCs is the molecular determinant for 
the identification of a side-population (SP) by flow cytometry based on the extrusion of 
certain dyes, such as Hoechst 33342 and Rhodamine 123 [61, 62]. Isolation of CSC through SP 
is a widely used method and supported by a variety of studies that revealed the presence of 
SP fraction in diverse human tumors, namely glioma [63], breast [64], ovarian and 
gastrointestinal cancers [65, 66]. Moreover, studies performed in our group, show the high 
expression of this drug efflux transporter and of P-glycoprotein (Pgp) other transmembrane 
transporter belonging to the ABC superfamily in human OS [67]. 
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The identification of CSCs based on the ALDH1 expression was successfully applied to a 
hematopoietic stem cell population by Storms and collaborators (1999). These cells have high 
expression of ALDH1, a cytosolic enzyme that is responsible for oxidizing a variety of 
aldehydes into carboxylic acids; ALDH1 can also catalyse the conversion of vitamin A to 
retinoic acid, which is involved in stem cell differentiation [68, 69]. High levels of ALDH activity 
have been shown to characterize highly clonogenic, undifferentiated multipotential 
stem/progenitor cells and  has been detected in many cancers including breast [70], liver [71], 
colon [72], AML [73] and OS [74] suggesting the presence of a subpopulation of cells with 
stem-like features. 
Another functional method widely used to isolate CSCs is the sphere forming assay based 
on the ability of undifferentiated cells to form spherical colonies when cultured in serum-free 
medium under anchorage-independent conditions. Under these stressful growth conditions 
of anchorage independence and serum starvation, only undifferentiated cells can proliferate 
growing as spherical colonies in suspension, whereas differentiated cells are unable to 
proliferate and died. These spherical colonies enriched in stem-like cells, can long-term self-
renew by serially passages and differentiate along multiple lineages which are defining 
properties of CSC. This method firstly performed for neural stem cells isolation has been used 
successfully with minor modifications, in the isolation of CSCs derived from a variety of 
tumors, including breast, neuronal and also in bone tumors [37, 75]. 
Gibbs and collaborators (2005) were the first to demonstrate the existence of CSC in OS 
through the sphere forming assay. These authors observed the formation of spherical 
colonies designed as sarcospheres when cultured in serum-free methylcellulose-based 
medium in the presence of growth factors and under non-adherent conditions. The 
sarcospheres expressed pluripotency markers characteristic of embryonic stem cells, further 
supporting the hypothesis that bone tumors contain cells with attributes of stem cells that 
can be isolated using the sphere-forming assay [36]. 
Studies performed by Martins-Neves et al., in our laboratory, using identical methodology 
with few alterations, demonstrated the presence of sarcospheres in another OS cell line – 
MNNG/HOS. Those cells, not only express pluripotency markers Oct4 and Nanog, but can also 
differentiate towards osteogenic, chrondrogenic and adipogenic lineages when cultured in 
specific differentiating conditions; which reveal their multipotency towards mesenchymal 
lineages, a MSC characteristic. 
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1.2.2 Therapeutic Implications of CSCs 
The existence of CSCs in tumors has significant therapeutic implications, once these cells 
possess several characteristics that turn them more resistant to conventional therapy 
relatively to their more differentiated tumorigenic counterparts. Features comprising relative 
dormancy/slow cell cycle kinetics, efficient DNA repair mechanisms, expression of specific 
drug-detoxifying enzymes, over expression of multidrug resistance related membrane 
transporters, resistance to apoptosis and protection by a hypoxic niche environment, with 
high production of free-radical scavengers can provoke the resilience of CSCs in the tumor 
[76]. Despite the considerable cytotoxicity of conventional chemotherapeutic drugs, not all 
cells present in tumor bulk are chemosensitive preventing an efficient eradication of tumor 
cells that subsequently leads to recurrence in following treatment [77]. Increasing evidence 
point out CSCs as resistant to both conventional chemo and radiotherapy and responsible for 
the recurrences commonly observed in cancer patients. The studies of Martins-Neves et al., 
identified a resistant phenotype to both chemo and radiotherapy in sarcospheres isolated 
from the MNNG/HOS OS cell line [19]. 
As mentioned above CSCs can acquire resistance to chemotherapy and radiotherapy 
through a range of mechanisms already described. CSCs are recognized for their capacity to 
enter in a quiescent non-dividing G0-state, without losing their proliferative ability, which 
appears to be necessary for preserving the self-renewal ability of stem cells. This feature is a 
critical factor in the resistance of CSCs to chemotherapy, since conventional 
chemotherapeutic agents target preferentially cells with high proliferative activity. CSCs that 
survive chemotherapy re-enter the cell cycle and initiate a cell division process that re-
initiates the tumor growth [77]. 
Another feature of these cells, which confers their resistance to chemotherapy, is the high 
expression of drug efflux transporters from the ABC gene family, including P-glycoprotein 
(Pgp) and breast cancer resistance protein (BCRP). These pumps allow normal stem cells to 
preserve their genome protecting them against chemical agents. Data obtained by Martins-
Neves et al. studies demonstrate a significant high expression of Pgp and BCRP in CSCs 
derived from human OS cell line compared to parental cells, which could explain the higher 
resistance of CSCs to chemotherapeutic agents (DOX and MTX). The reversal of resistance to 
chemotherapy with a non-specific inhibitor of ABC transporters and a transport substrate of 
Pgp and BCRP pumps sustain the hypothesis that up-regulation of such transporters prevents 
the intracellular accumulation of chemotherapeutic agents at toxic levels resulting in 
resistance [19]. SP cells can be isolated from a variety of cancer cell lines namely breast, 
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hepatocellular, gastrointestinal and thyroid that have shown high expression of ABC 
transporters when compared to the non-SP cells [62]. 
Moreover, those CSCs possess highly activated DNA repair mechanisms and possibly 
enhanced efficiency on DNA damage response activity. This property turns these CSCs 
radioresistant since they have enhanced capacity to repair lethal damages and present 
decreased production of ROS potentially as a result of increased levels of free radical 
scavengers. Furthermore, this capacity restrains them from undergoing apoptosis even with 
higher doses of irradiation and drugs [19]. In glioma patients with CD133+ stem cells, those 
cells conferred resistance to radiotherapy with a more efficient mechanism of DNA damage 
repair and underwent less apoptosis [80]. 
Activation of apoptotic programme has been shown to be responsible for chemo- and 
radiation induced cytotoxicity in tumor cells, whereas inactivation of apoptosis signaling 
pathways help CSCs to evade the cytotoxicity activity of most anticancer therapies [54]. 
Recent studies in our laboratory, demonstrated that CSCs isolated from an MNNG/HOS OS 
cell line display increased resistance to DOX-inducing apoptosis as compared with parental 
cells, due to defects in the apoptotic mitochondrial signaling pathway. Analysis of the 
expression levels of the pro-apoptotic and anti-apoptotic proteins following exposure to DOX 
showed a significant overexpression of the anti-apoptotic proteins Bcl-2 and Bcl-XL 
simultaneously with a reduction of pro-apoptotic protein Bak in CSCs in relation to parental 
cells [82]. 
Similar results were observed by Liu and collaborators (2006) in glioma cells that found high 
levels of Bcl-2 and Bcl-XL in CD133+ cells as compared with the  non-stem cell fraction CD133- 
cells, further supporting the hypothesis that alteration in apoptosis pathways contribute for 
chemotherapy resistance in CSCs [78, 83]. 
All these studies suggest that CSCs have molecular pathways that promote their survival 
which increase the urgency to develop new therapies targeting specifically CSCs and achieve 
their ablation from the tumor [78]. 
Despite the current treatment with chemotherapy could shrink the tumor bulk the CSCs 
remain unharmed and following treatment these CSCs can self-renew and reshape the bulk 
of tumor leading to tumor recurrence as depicted in Figure 1.6 (a). However, whether a CSC-
targeted therapy is combined with conventional therapy, CSCs would be killed and the tumor 
bulk also shrunk. Post-therapy any remaining non-CSCs could divide but with limited 
proliferative capacity and cells capable to reform the tumor bulk would be eliminated, so 
tumor recurrence would not occur as demonstrated in Figure 1.6 (b) [14]. 
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Figure 1.6. Impact of the CSCs model on anti-tumorigenic therapy. A) Chemotherapy alone shrinks 
the tumor bulk. However, CSCs that is chemoresistant might survive to this therapy and then can self-
renew and differentiate in order to reform the tumor bulk. B) Combined chemotherapy will not only 
kill the tumor cells but also the CSCs. The remaining non-CSC tumor cells will die due to their limited 
proliferation capacity and the complete eradication of the tumor was achieved. (Adapted from Siclari 
et al., 2010) 
 
 
 
 
 
1.3 Metformin 
Metformin (METF, 1, 1-dymethylbiguanide hydrochloride) is an insulin-sensitizing semi-
synthetic biguanide with two methyl groups binding to the nitrogen nucleus as shown in 
Figure 1.7. This compound is derived from the hypoglycemic substance galegine and has 
potent antihyperglycemic properties [84]. 
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Figure 1.7.Chemical structure of Metformin. A semi-synthetic biguanide with two methyl groups 
binding to the nitrogen nucleus. (Adapted from Ruggiero-Lopez et al., 1999) 
 
METF is one of the most prescribed drugs to treat type II diabetes. This drug exerts its 
antidiabetic effects by decreasing hepatic glucose production and by increasing insulin 
sensitivity as well as glucose uptake and utilization by peripheral tissues [85]. The mechanism 
behind these actions is thought to be mediated by the inhibition of the mitochondrial 
oxidative phosphorylation leading to ATP/AMP imbalance, which results in the activation of 
AMP-activated protein kinase (AMPK), a central regulator of metabolic pathways. AMPK 
activation results in the inhibition of protein synthesis and gluconeogenesis during cellular 
stress.  
Other indications of METF treatment include polycystic ovarian syndrome (PCOS), where 
insulin resistance is a key factor for development of metabolic disturbances, and the 
management of metabolic syndrome and diabetes prevention in high-risk populations [85]. 
In the past decade METF has gained special attention for its anticancer properties. 
Epidemiological studies have found that type 2 diabetic patients have an increased risk of 
developing liver, pancreatic, colorectal, endometrial, kidney, urinary, bladder and breast 
cancer. Insulin resistance and associated mitogenic hyperinsulinemia connect diabetes, 
obesity and metabolic syndrome with cancer. Numerous population-based epidemiological 
studies have found a lower incidence of cancer and lower mortality related with cancer in 
diabetic patients who have been treated with METF in comparison with patients that had 
been treated with other anti-diabetic drugs [84]. 
These epidemiological studies were performed in different tumor types including among 
others endometrial, colorectal or pancreatic carcinomas. More patients with colorectal and 
pancreatic carcinomas who had been treated with METF showed a 30% improvement in 
survival when compared with patients treated with other anti-diabetic agents [84, 89]. In 
addition, early epidemiological studies suggested an inverse relationship between diabetes 
and prostate cancer, presenting a 44% risk reduction of prostate cancer incidence in 
Caucasian men on METF therapy [84]. 
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These findings from retrospective clinical studies suggest that METF may be associated with 
a decrease risk of developing cancer and with a better response to therapy, increasing the 
initial interest of METF as an anticancer agent. In fact, METF have received on last years, 
particular attention for its potential anti-tumorigenic effects that are thought to be 
independent of its hypoglycemic activity, and was recently suggested as an adjuvant 
treatment for cancer or gestational diabetes, and for the prevention in pre-diabetic 
populations.  
Moreover, a retrospective study showed an increase in the effectiveness of neoadjuvant 
chemotherapy in breast cancer patients who took METF concomitantly with systemic therapy 
in patients with and without diabetes [84, 85]. 
 
1.3.1 Anti-cancer mechanisms of METF 
The beneficial effects and potential mechanisms of METF in treatment of cancer have been 
attributed mainly to the activation of the AMPK/mTOR pathway under control of LKB1. LKB1 
is serine-threonine acting as a tumor suppressor protein that is somatically inactivated in a 
variety of tumors. METF action in glucose metabolism is mediated through the activation of 
the tumor suppressor gene LKB1 in liver, as been suggested by Kourelis et al.  Once activated 
LKB1 phosphorylates AMPK, which is inactive unless it is phosphorylated by upstream kinases 
in response to cellular metabolic stress. A direct consequence of the activation of AMPK is 
the inhibition of the mammalian target of rapamycin (mTOR), a downstream effector of 
growth factor signaling via tuberous sclerosis 2 protein (TSC2). mTOR is involved in regulating 
consuming cellular processes and plays a critical role in modulating cell growth and 
proliferation by controlling mRNA translation and ribosome biogenesis.  The inhibition of 
mTOR decreases phosphorylation of S6 kinase, ribosomal protein S6 and eIF4E-binding 
protein 1, leading to cell cycle arrest and growth inhibition [85]. 
Cancer cells are more sensitive to nutrient starvation than non-malignant cells. Since AMPK 
is a major regulator of cell metabolism, it is activated by any condition that increases the ratio 
of AMP/ATP, leading to suppression of cellular metabolism and cellular proliferation. AMPK 
phosphorylates substrates which inhibit anabolic processes and induce catabolic processes 
to reverse the high AMP/ATP ratio. METF blocks the complex I of oxidative phosphorylation, 
which provokes an increase in NADH/NAD+ ratio and blocks the fatty-acid β-oxidation and 
subsequent increase of AMP/ATP ratio. Due to this activation, AMPK inhibits protein 
synthesis by inhibition of both elongation factor-2 and mTOR pathway.  AMPK 
phosphorylates TSC2 that form a tumor suppressor complex, TSC2-TSC1, and the TSC2 
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subunit inhibits Rheb GTPase activity leading to mTOR inhibition with a subsequent decrease 
in cell growth and proliferation. This METF’s action may provide an explanation for its 
neoplastic actions. Furthermore, AMPK activation assists in adaptation to metabolic stress 
not only by cell growth and proliferation inhibition but also by inducing cell cycle arrest 
and/or apoptosis through p53 phosphorylation [85, 86, 92]. 
Activation of AMPK by METF has been shown in a variety of cancers, such as pancreas [91], 
breast [92], melanoma [93] and thyroid carcinoma [94]. 
 
Some studies performed in muscle tissue show that treatment with METF can induce a 
reduction in GLUT-1 content and this METF’s action involves the subcellular redistribution of 
GLUT-1 in the skeletal muscle. However, METF treatment had no effect on the subcellular 
distribution of another transporter, the GLUT-4. Probably this is the main effect of METF to 
lowering the plasma glucose levels, however the main action is unknown [95]. Malignant cells 
have accelerated metabolism, high glucose requirements and increased glucose uptake. The 
increased glucose transport in malignant cells has been associated with increased and 
deregulated expression of glucose transporter (GLUT) proteins, with main characteristic 
features the overexpression of GLUT-1 and/or GLUT-3. Each of the GLUT proteins possesses 
different affinities for glucose and others hexoses. GLUT-1 and GLUT-3 have a high affinity for 
glucose, enabling a high rate of transport of glucose under physiological conditions. Since 
tumor has higher rates of glycolysis there is an increase activity of enzymes involved in 
glycolysis. Furthermore, upregulation of GLUT-1 and GLUT-3 expression occurs in the 
transformation process and could be a key role in the neoplastic process [96]. Furthermore, 
have been shown the presence of GLUT-1 and GLUT-3 in OS cell lines. In OS, insulin stimulates 
glucose transport due to increased GLUT-1 mRNA expression and increased expression of 
GLUT-1 protein [97]. So, METF could have an effect in cancer glucose uptake, which varies 
with tumor characteristics. 
 
Other mechanisms include the induction of cell cycle arrest and apoptosis independently of 
AMPK activation. It was found that METF blocked cell cycle progression in G0/G1 phase in 
glioma cells and reduced levels of cyclin D1 in prostate cancer cells and blocked cell cycle in 
G0/G1 phase without AMPK activation. Furthermore, in pancreatic cancer cells METF was able 
to induce apoptosis by activation of the caspase pathway [85, 89]. 
In addition, increased levels of insulin growth factor 1 (IGF1) are associated with malignant 
transformation and tumorigenesis. Additionally, IGF1 has been shown to inhibit 
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chemotherapy-induced apoptosis by activation of the PI3K/Akt pathway. Since METF 
increases peripheral insulin sensitivity, thereby reverses hyperinsulinemia and inhibits the 
negative feedback of insulin on insulin growth factor binding protein (IGFBP1), IGF1 could be 
a useful target for METF’s antineoplastic treatment. By applying METF therapy the reduction 
in insulin levels results in increased IGFBP1 levels. Consequently, IGF does not binds to its 
receptor and is not able to activate the PI3K/Akt/mTOR pathway, which plays a role in the 
control of protein synthesis and cell proliferation, leading to a decrease in tumor growth and 
proliferation [86]. Besides, Kourelis et al. (2012) demonstrated that METF did not activate 
AMPK in lung tissue but inhibited phosphorylation of insulin growth factor-I receptor (IGF1R), 
Akt and mTOR, supporting the hypothesis that METF could have other targets to achieve its 
anti-carcinogenic action [85]. The main actions of METF are depicted in Figure 1.9. 
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Figure 1.8. Possible mechanisms underlying METF inducing anticancer activity. Activation of AMPK 
by METF inhibits mTOR, induces cell cycle arrest and inhibits protein synthesis. METF could acts 
independently of AMPK through phosphorylation of cyclin D1 and p53, decreasing circulating insulin 
levels and exerting toxic effects on CSCs. (Adapted from Kourelis et al., 2012) 
 
Recent studies suggest that METF is preferentially toxic to CSCs. One of the proposed 
mechanisms of this effect in breast cancer is based on METF’s ability to decrease systemic 
metabolic biomarkers such as insulin, IGF1 and estradiol, which are components of the 
mitogenic niches and regulators of the generation and/or maintenance of CSCs in their niche 
[84]. 
Bao and collaborators (2011) show that METF could specifically affect the formation of CSCs 
and their self-renewal ability from pancreatic cancer cells interfering with the expression of 
markers of CSCs, namely CD44 and EpCam, altering their genetic or epigenetic plasticity. 
Further in this study, the authors show that METF could decrease the gene expression of 
Enhancer of Zeste Homologue 2 (EZH2) which is a histone methyltransferase involved in 
epigenetic regulation of gene transcription. Overexpression of EZH2 is related with de novo 
suppression of multiple genes in human cancers and might cause normal cells to 
dedifferentiate into stem cell-like by epigenetically repressing cell fate-regulating genes and 
tumor suppressor genes, which promotes the development of tumors. As well as EZH2, the 
expression levels of CD44, Oct4 and other pluripotency and stemness markers of CSCs were 
decreased after CSCs were treated with METF [88]. These studies suggest that treatment with 
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METF can decrease the capacity of sphere forming in breast and pancreatic cancer, an effect 
that was equally observed in lung and prostate cancers [88, 98, 100]. 
Moreover, METF have been implied in the Wnt/β-catenin signaling pathway regulation 
through AMPK activation. Unpublished data performed in our group, confirm the expression 
of β-catenin in CSCs derived from human OS cell lines. Since METF have been shown to 
attenuate Wnt/β-catenin signaling by reducing β-catenin protein levels in OS and also that β-
catenin is expressed in CSCs from OS, can be suggested that METF acts on CSCs trough 
regulation of survival pathways [99]. Hirsch and collaborators (2009) show  that  the  
combination  of  METF  with the chemotherapeutic agent DOX  kills  both  CSCs  and  non-
stem  cancer  cells populations  in  culture  and also provokes a reduction in tumor growth 
and prolonged remission in vivo [99]. In  addition,  the  combination  of  these  two  drugs  
increased the  efficacy  of  therapy  and diminished the side effects. Hence, an important 
effect of METF is decreasing the doses of conventional chemotherapeutic agents without 
decreasing their effectiveness, namely DOX [100]. 
Although typically the antitumorigenic effect of METF has been attributed to its ability to 
activate the LKB1/AMPK/mTOR pathway as well inhibition of insulin-growth mechanisms, the 
mechanism of action of this drug is complex and involve a multiple a variety of molecules and 
pathways with key roles in cell growth and survival [85].     
 
1.4 Objectives 
The main objective of this study was to explore the potential role of METF as adjuvant of 
DOX for targeting CSCs in OS. To achieve this goal we propose to: 
 Isolate subpopulations of cancer stem cells (CSCs) in two human OS cells lines 
(MNNG/HOS and MG-63) using the sphere formation assay; 
 Evaluate the effect of METF on cell viability, proliferation and metabolic activity; 
 Evaluate the effect of METF on sphere formation and self-renewal abilities of CSCs; 
 Evaluate the chemosensitizing effect of METF on cytotoxicity of DOX in parental cells and 
CSCs; 
 Explore the signaling pathways underlying the anticancer properties of METF in OS CSCs.  
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2.1. Cell Culture 
The human osteosarcoma cell lines MNNG/HOS and MG-63 was obtained from the 
American Type Culture Collection (ATCC, Rockville, MD). Cells were cultured in monolayer 
with RPMI-1640 medium (R4130, Sigma-Aldrich®, St. Louis, USA) supplemented with 10% 
(v/v) of heat-inactivated fetal bovine serum (FBS, 10270-106, Gibco® Invitrogen Life 
Technologies), 1% (v/v) antibiotic/antimicotic containing 100 mg/ml streptomycin, 100 
units/ml penicillin and 0.25 µg/ml amphotericin (A5955, Sigma-Aldrich®, USA) at 37°C in a 
humidified atmosphere with 5% CO2 and 95% air. Cells were subcultivated at a ratio of 1:5 
twice a week when the cells reached approximately 80% of confluence. This procedure was 
made in sterile conditions in a laminar flow chamber.  
 
2.1.1. Cell Counting and Viability  
Cell counting and viability was determined before all experiments through the trypan blue 
exclusion method. For this procedure equal volumes of cell suspension and trypan blue 0.4% 
(Sigma-Aldrich®) (20µl) were mixed, transferred into a Neubauer chamber hemocytometer 
(Marienfeld, Germany) and then were observed and counted in an inverted microscope 
(Nikon, Eclipse TS 100). This experiment is based on the principle that viable and live cells 
with intact cell membranes can exclude the dye, while dead or injured cells with damaged 
membrane do not. In accordance with this, viable cells emerge brilliant with clear cytoplasm 
whereas nonviable cells appear blue. Cell viability was calculated as a percentage of viable 
cells relative to the total number of cells. Only cells exhibiting viability > 90% were used in all 
experiments. 
 
 
2.2. Sphere Formation Assay 
CSCs were isolated from MNNG/HOS and MG-63 parental cell lines through the sphere-
formation assay in which cells were cultured in serum-free medium under anchorage-
independent conditions as described elsewhere. [19] MNNG/HOS and MG-63 cells at a 
confluence of approximately 80% were detached with trypsin- ethylenediaminetetraacetic  
acid (EDTA) (T4049, Sigma-Aldrich®) and seeded at a density of 30×103 cells/mL in Petri culture 
dishes  previously coated with 2.7 mg/cm2 of Poly-HEMA (P3932, Sigma-Aldrich®) solution, 
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containing 13 mL of N2 medium with 1% methylcellulose (M0837, Sigma-Aldrich®). The N2 
medium consists of Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 Ham 
(DMEM/F12, D2906, Sigma-Aldrich®) supplemented with 1.2 g/L sodium bicarbonate (S6297, 
Sigma-Aldrich®), 20 nM progesterone (P7556, Sigma-Aldrich®), 100 µM putrescine (P5780, 
Sigma-Aldrich®), 1% (v/v) insulin-transferrin-selenium-A supplement (Gibco® Invitrogen Life 
Technologies) and 1% (v/v) antibiotic/antimicotic. This medium was mixed with equal volume 
of sterile 2% methylcellulose solution to avoid the single-cell aggregation. Fresh aliquots of 
human epidermal growth factor 10 ng/mL (EGF, E9644, Sigma-Aldrich®) and of human basic 
fibroblast growth factor 10 ng/mL (bFGF, Prepotech EC, London, UK) were added twice a 
week. Cells were maintained at 37°C in a humidified atmosphere of 5% CO2 and 95% air for 
7-10 days. 
After that, the spherical colonies formed were removed and transferred to adherent 
surfaces (T25 flasks, Orange Scientific, Belgium) and cultured in DMEM Low Glucose (Gibco® 
Invitrogen Life Technologies) medium supplemented with 10% of Mesenchymal Stem Cell-
qualified serum (MSC), 2 mM Glutamine (59202C, Sigma-Aldrich®) and 1% (v/v) 
antibiotic/antimicotic. After reaching 70-80% confluence, cells were re-seeded as single-cell 
in serum-free medium and in non-adherent conditions for secondary sphere forming assay. 
This procedure was repeated three times for evaluating the self-renewal capacity of spheres. 
Second or third generation spheres were used in subsequent experiments and were termed 
as sarcospheres or CSCs. 
 
 
2.3. Immunofluorescence assay 
The expression and sub-cellular localization of the pluripotency transcription factors Oct4 
and Nanog was analysed by immunofluorescence. Both parental (MNNG/HOS and MG-63) 
and corresponding CSCs were plated at a density of 150×103 and 130×103 cells/well, 
respectively, in 6-well plates covered with coverslips. After 48 hours the culture medium was 
removed and the cells washed with PBS (3 x 5min). After that the cells were fixed with 4% 
paraformaldehyde (PFA, P6148, Sigma-Aldrich®), during 10 minutes at room temperature and 
then washed with PBS (3 x 5min). After fixation cells were permeabilized during 10 minutes 
with 1% Triton-X at room temperature and subsequently washed with PBS (3 x 5 min) 
followed by incubation with blocking buffer (goat serum diluted in PBS/0.02% BSA) during 30 
minutes in a humidified chamber. After blocking, cells were incubated with primary antibody 
diluted in PBS/0.02% BSA during 1 hour at room temperature, in a humidified chamber. The 
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primary antibody solution was removed and cells washed with PBS (3 x 5 min). After that cells 
were incubated with Alexa Fluor 594-labeled goat anti-rabbit IgG secondary antibody diluted 
in PBS/0.02% BSA during 1 hour at room temperature, in a humidified chamber protected 
from light. Afterwards, cells were washed with PBS (4 x 5 min) and incubated with 5 µg/mL 
Hoechst solution during 5 minutes for nuclei staining. Finally the cells were washed (3 x 5 
min) in the dark, and the coverslips were mounted with Dako and sealed with nail polish. 
Images were captured on a confocal microscope (LSM 710 META, Carl Zeiss, Gottingen, 
Germany). 
 
 
2.4. Cytotoxicity Studies to DOX and METF 
Both parental MNNG/HOS and MG-63 cells and corresponding CSCs where assayed to their 
sensitivity to DOX, which is the most widely chemotherapeutic agent used in the treatment 
of OS, and METF as single agents or in combination. The cytotoxicity of DOX was analysed 
using the [3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide] (MTT) 
colorimetric assay, a widely used method to assess cell viability. The effect of METF was 
analysed on cell viability using the MTT assay and on cell proliferation using the 5-bromo-2’- 
deoxyuridine (BrdU) incorporation assay. Since we intend to explore the synergy between 
METF and DOX on cell viability, the effects of the combined drugs was evaluated using the 
MTT assay. 
Both parental MNNG/HOS and MG-63 and corresponding CSCs, previously expanded in 
adherent conditions and at 70% confluence, were detached with trypsin/EDTA, counted and 
seeded in 96-well plates (Sarstedt, Inc. Newton, USA) at a density of 7500 cells/well for 
MNNG/HOS and corresponding CSCs and 6000 cells/well for MG-63 and corresponding CSCs. 
Plates were maintained at 37°C overnight to allow the attachment of cells. 
Next day, cells were incubated with different concentrations of drugs as a single dose and 
combined as described in Table 2.1. 
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Table 2.1 Drug concentrations and combinations used in cytotoxicity assays. 
 
Single dose Combined drugs 
DOX (µM) METF (mM) DOX (µM)      +     MET (mM) 
0.0001 0.05 
0.25  
0.05 
0.1 
1 
2 
5 
0.01 0.1 
0.10 1 
0.25 2 
0.50 5 
0.50  
0.05 
0.1 
1 
2 
5 
1  
5  
10  
50  
1.0 
0.05 
0.1 
1 
2 
5 
100  
  
 
 
 
Stock solution of DOX (DOXO-cell®, 2mg/mL) was diluted with PBS at appropriate working 
concentrations before adding to the cells. A stock solution of METF (Sigma-Aldrich) was 
prepared in PBS at a concentration of 1 mg/mL and was then filtered and diluted to yield the 
appropriate working concentrations. 
  
2.4.1. Cell Viability Studies – MTT colorimetric Assay 
Cell viability was determined using the MTT colorimetric assay. This experiment is based on 
the reduction of the yellow tetrazolium salt into purple formazan crystals by the 
mitochondrial enzyme succinate dehydrogenase of metabolic active cells, enabling the 
quantification of viable cells [102]. The amount of formazan crystals formed can be 
measured, after dissolution with acidified isopropanol, spectrophotometrically using an ELISA 
microplate reader. The colour intensity resulting from dissolution of formazan crystals is 
proportional to the enzyme activity and consequently to the number of viable cells. 
Cell viability was determined after 48 h of treatment with DOX or METF as single doses and 
in combination as described in table 2.1. The culture medium was removed and 50 µL of MTT 
solution 0.5 mg/mL (M2128, Sigma-Aldrich®) were added to each well. The cells were further 
incubated at 37°C in the dark during 4 hours, the necessary time for the reduction of MTT 
with consequent formation of formazan crystals. Then, 50 µL of acidified isopropanol (0.04 
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M HCl) were added in order to dissolve the formazan crystals. The absorbance was read in an 
automatic ELISA microplate reader at 570nm with a reference filter of 620 nm. 
The percentage of viable cells relatively to the controls was calculated using the following 
formula (1). Untreated or DOX-treated cells were used as controls for single-dose and drug 
combination studies, respectively. 
 
                        (1) 
 
 
The chemosensitivity of both parental and CSCs to DOX was estimated based on the 
calculation of the concentration of DOX needed to inhibit cell viability in 50% (IC50). A dose-
response curve was plotted on a semi-log scale with a percentage of viable cells versus 
concentration of DOX and fitted to a sigmoidal function, accordingly with the equation (2).  
 
 (2) 
 
 
Where A1 and A2 are the bottom and top asymptotes, respectively, and x0 is the IC50 and p 
the slope. The curve fitting was performed using GraphPad Prism software Version 5.0. 
 
2.4.2. Cell Proliferation Studies – BrdU colorimetric Assay 
The effects of METF on cell proliferation were evaluated using the 5-bromo-2’- deoxyuridine 
(BrdU) incorporation assay. BrdU is a synthetic nucleoside analogue of thymidine that is 
incorporated into the newly synthesized DNA in proliferating cells. The assay was carried out 
after the 48h incubation with METF using a commercial kit of Cell Proliferation ELISA, BrdU 
(Roche®, Germany) according to the manufacturer instructions. After cells treatment, the 
culture medium was removed and the cells were incubated with 100 µL of fresh medium 
containing 10 µL of BrdU solution (100 µM) at 37°C with 5% CO2 during 3 hours. After that 
the medium containing BrdU was removed and the cells were incubated with 200 µL/well of 
fixative solution (FixDenat) during 30 minutes at room temperature to denature the DNA. 
Then, the fixative solution was removed and cells were incubated with 100 µL/well of anti-
BrdU-POD solution, during 90 minutes at room temperature. Finally, cells were washed 3 
times with 200 µL/well of washing solution and were incubated with 100 µL of substrate 
solution for 30 minutes at room temperature. The absorbance was read in an ELISA reader at 
370 nm with a reference filter of 492 nm. Absorbance values were expressed as percentages 
relative to untreated controls. 
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2.4.3. Analysis of combined drugs effect 
CompuSyn software was used to calculate the combination indices (CI) that indicate 
whether the effect of two drugs combination is higher than either alone, using the dose-
response curves for each drug and the combination. CI values less than 0.85 indicate 
synergism, values equal to 0.90 indicates additivity and values greater than 1 indicates 
antagonism. 
 
 
2.5. Cellular metabolic activity - [18F]FDG uptake 
The metabolic activity of both adherent OS cells (MNNG/HOS and MG-63) and 
corresponding CSCs was assessed using [18F] fluoro-2-deoxyglucose ([18F]FDG), which is a PET 
radiopharmaceutical analogue of glucose approved by Food and Drug Administration (United 
States of America) for routine clinical PET imaging studies. 
Cells were seeded in 6-well plates at a density of 150×103 cells/well and allowed to attach 
overnight. Then, cells were incubated with increasing concentrations of METF (0.05-5 mM) 
during 48 hours. After this period, [18F]FDG (0.75 MBq/mL) was added to the culture medium, 
and the cells were incubated for 1 hour in a humidified incubator at 37°C with 5% CO2. 
Afterwards the culture medium was collected to glass tubes. The cells were washed twice 
with PBS, scraped and collected into glass tubes. Both tubes containing the collected culture 
medium and washing solutions or the scrapped cells were assayed for radioactivity in a 
Radioisotope Calibrator Well Counter (CRC-15W Capintec, USA) within the 18F sensitivity 
energy window of 400-600 keV.  
After reading radioactivity, cells were lysed with 1% SDS (m/v) in PBS (pH 7.0) and the total 
protein was quantified using the bicinchoninic acid (BCA, B9643, Sigma-Aldrich®) method with 
bovine serum albumin (BSA, A2153, Sigma-Aldrich®) as a standard in a 96-well cell culture 
plate that were used to generate a calibration curve. The reaction was incubated at 37ºC for 
30 min. The absorbance was read at 570nm in an ELISA microplate reader. Results are 
reported as the percentage of cell radioactivity in relation to the total radioactivity added and 
were normalized per gram of protein. The cellular uptake of [18F]FDG was expressed as a ratio 
to the levels found in METF treated cells to untreated cells. 
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2.6. Effects of METF on sphere-forming ability and self-renewal potential 
To examine whether METF interferes with the sphere-formation ability of MNNG/HOS and 
MG-63 cells, we performed a sphere-forming assay as previously described in section 2.2 in 
the presence of METF at concentrations varying from 0.05 mM to 5 mM.  
To further evaluate the effects of METF on the self-renewal of CSCs, which is a critical 
property of stem-like cells, first generation spherical colonies were enzymatically dissociated 
and platted in N2 serum-free medium containing METF (0.05 mM to 5 mM) in non-adherent 
surfaces to induce the formation of secondary spheres. 
After 7-10 days in culture, the spherical colonies were observed and counted in an inverted 
microscope (Nikon, Eclipse TS 100). The sphere-forming efficiency (SFE) was calculated as the 
number of spheres formed divided by the original number of single cells seeded and 
expressed as the percentage. The sphere-size and morphological appearance was also 
evaluated. Images of the spherical colonies were acquired in a fluorescence microscope 
(Leica DFC350 FX, Leica Microsystems, Bannockburn, IL, EUA).  
 
 
2.7. Analysis of Protein Expression by Western Blot 
 
2.7.1. Expression of energy sensor AMPK and downwards targets 
In order to explore whether exposure to METF induce the activation of AMPK, a major 
energy sensor in the cells, and lead to the inhibition of mTOR with consequent interference 
in protein synthesis and cell proliferation, we analysed the expression levels of the activated 
form of AMPK and mTOR in both parental and corresponding CSCs after 48h treatment with 
METF at different concentrations. 
With this purpose, cells dissociated from sarcospheres and parental cell lines (MNNG/HOS 
and MG-63) were seeded in 6-well cell cultures plates (Orange Scientific, Belgium) in their 
corresponding culture medium at a density of 150×103 cells/well and allowed to attach 
overnight. Five increasing concentrations of METF ranging from 0.05mM to 5mM were added 
to each well. After 48 hours, the cellular extracts were prepared and the proteins analysed 
by Western Blot accordingly with the description in the section below. 
 
2.7.1.1. Preparation of cellular extracts 
The total extracts of MNNG/HOS and MG-63 and corresponding CSCs were prepared in the 
control situation and after 48h exposure to METF in the concentrations above mentioned. 
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Cells with a confluence of 70-80% were washed and scraped with PBS and then were 
centrifuged at 1400 rpm for 10 minutes. The cellular pellets were incubated with lysis buffer 
– RIPA [50mM Tris-HCl(pH 8.0), 150mM NaCl (Merck), 1% (v/v) Triton X-100, 0.5% (w/v) 
sodium deoxycholate, 0.1% (w/v) sodium dodecyl sulphate (SDS, 161-0307, Bio-RadTM) and 
2mM EDTA], supplemented with a mixture of proteases and phosphatases inhibitors 
(Roche®), 2mM sodium orthovanadate, 1mM sodium fluoride (NaF) and 1mM dithiotreitol 
(DTT). After incubation for 30 minutes at 4°C in RIPA buffer, samples were sonicated dipped 
in ice in an ultrasound device (Vibra cell Sonics and Materials Inc. Danbury, CT USA) at 40 
MHz, with 3-5 pulses for 5 seconds.  
The protein concentration was quantified using the bicinchoninic acid (BCA, B9643, Sigma-
Aldrich®) method with BSA (A2153, Sigma-Aldrich®) as a standard in a 96-well cell culture 
plate. This experiment is based on the formation of protein/Cu2+ complexes under alkaline 
conditions, followed by reduction of Cu2+ to Cu1+. This reduction is proportional to the amount 
of protein present in the sample. Under alkaline conditions, the chelation of BCA with Cu1+ 
develop a blue/purple complex, which can be read in an automatic ELISA microplate reader 
at a wavelength of 562 nm [103]. 
The protein samples were mixed with an equal volume of 2x denaturing solution [0.25M 
Tris-HCl (pH 6.8), 200mM DTT, 20% (w/v) glycerol (G2025, Sigma-Aldrich®), 4% (w/v) SDS and 
0.05% (w/v) bromophenol blue], and were heated at 95°C during 5 minutes for protein 
denaturation. The protein samples were stored frozen at -20°C until their use.   
 
2.7.1.2. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
and electro-transference 
Polyacrylamide gel preparation implies the crosslinking of acrylamide monomers used to 
support and separate the molecules based on size, shape or isoelectric point. The samples 
were loaded in SDS-polyacrylamide gels [7.5 or 12% of acrylamide (161-0148, Bio-RadTM)] and 
separated by electrophoresis during 90 minutes at 110V in buffer solution of 50mM Tris-HCl 
(pH 8.0-8.5) containing 50 mM bicine (B3876, Sigma-Aldrich®) and 0.1% (w/v) SDS. 60µg of 
the total extract protein from parental cells (MNNG/HOS and MG-63) and corresponding 
CSCs were used for immunoblot assay. A protein marker with known molecular weight – 
Precision PlusProteinTM Standards (161-0373, Bio-RadTM) was used in the electrophoresis. 
After the electrophoresis, proteins were electro-transferred from the electrophoresis gel 
into hydrophobic polyvinylidenedifluoride membranes (PVDF,MilliporeTM, USA), previously 
activated in methanol (Merck, Germany). The electro-transference was performed in transfer 
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buffer [12.5mM Tris-HCl (pH 8.0-8.5) containing 96mM glycine (G8898, Sigma-Aldrich®) and 
20% (v/v) methanol], applying a current of 110V during 90 minutes at 4°C.  
 
2.7.1.3. Immunoblotting and Quantification 
After transfer, membranes were blocked with 5% (w/v) non-fat dry milk in Tris-Buffered 
Solution (TBS: 20mM Tris, pH 7.6, 137mM NaCl) containing 0.1% (v/v) Tween20 (437082, 
VWR®)(TBS-T) during 1 hour at room temperature with soft agitation in order to reduce the 
non-specific protein interactions and to reduce the background signal. After that, the 
membranes were incubated overnight at 4°C with primary antibodies at appropriate 
dilutions, as shown in Table 2.2, in Phosphate Buffer Saline (PBS pH 7.4) containing 0.1% (v/v) 
Tween 20 (PBS-T), containing 5% (w/v) BSA or in TBS-T containing 1% (w/v) non-fat dry milk. 
At the end of incubation period, membranes were washed 3 times for 10 minutes with PBS-
T and then incubated with alkaline phosphatase-conjugated secondary antibodies (anti-
mouse or anti-rabbit) for 1 hour at room temperature with agitation. Finally, membranes 
were washed again 3 times for 10 minutes with PBS-T and then revealed using the enhanced 
chemofluorescence substrate (ECF, Western blotting Reagent Pack, GE Lifesciences, 
Pittsburg, PA). The reactive bands were visualized on a Thyphoon FLA 9000 (GE Healthcare 
Bioscience, AB, Uppsala, Sweden) and were quantified using the ImajeJ software (Research 
Service Branch). The membranes were stripped using 0.2M NaOH for 5 minutes and then 
reprobed with anti-total-AMPK antibody in the case of pAMPK and with the anti-β-actin 
antibody as loading control, in the case of mTOR, followed by incubation with secondary 
antibody and revelation as described previously. The band intensities were normalized to 
their corresponding controls. 
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Table 2.2. Primary and secondary antibodies used on Western Blot, and corresponding dilutions. 
 
 
 
2.8. Statistical Analysis 
All the results were presented as mean ± standard deviation (SD) or as mean ± standard 
error of mean (SEM), with n indicating the number of experiments performed. The Kruskal-
Wallis non-parametric ANOVA test, with Dunnett’s correction, was performed for multiple 
comparisons within the same cell line throughout different conditions. The Mann-Whitney 
non-parametric test was used to perform comparisons between two cell types under the 
same conditions. The statistical analysis was performed by using the GraphPad Prism 
software Version 5.0. The p-value < 0.05 was considered as statistically significant. 
Primary 
Antibody 
Molecular 
Weight 
Dilution Company 
Secondary 
Antibody 
Dilution 
 
pAMPK 
 
 
62 kDa 
 
1:1000 
 
Cell Signaling Technology® 
 
Anti-Rabbit 
 
1:20000 
AMPK 
 
62 kDa 1:1000 Cell Signaling Technology® Anti-Rabbit 1:20000 
mTOR 
 
289 kDa 1:2000 MilliporeTM Anti-Rabbit 1:20000 
β-Actin 43 kDa 1:10000 MilliporeTM Anti-Mouse 1:20000 
      
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
RESULTS 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                        Chapter 3 – Results  
39 
 
3.1. Isolation and characterization of CSCs from MG-63 and MNNG/HOS 
cell lines  
3.1.1. Isolation of sarcospheres from human OS cell lines 
The presence of putative cells with stem-like properties in MNNG/HOS and MG-63 OS cell 
lines was identified through the sphere formation assay, in which parental cells were cultured 
in 1% methylcellulose serum-free medium, in anchorage-independent conditions. Under 
these conditions, both cell lines grew in suspension and formed spherical colonies, named 
sarcospheres as depicted in Figure 3.1. When transferred to adherent flasks and expanded in 
culture medium suitable for MSCs, cells started to migrate from the colonies and to adhere 
to the bottom of the flask. When re-seeded again in serum free-medium they formed 
secondary spherical colonies. This capacity to form spherical colonies was observed at least 
in a third round of sphere formation assay, which reveals the self-renewal ability of these 
cells which is considered an important characteristic of stem-like cells. Sarcospheres of 
second and third generation were used in succeeding studies and were termed as CSCs. 
Figure 3.1. OS parental cell lines form sarcospheres in serum-free medium under anchorage-independent 
conditions. A. Adherent MNNG/HOS parental cell line. B. Sarcospheres isolated from MNNG/HOS cell line 
after 7 days in non-adherent conditions. C. Adherent MG-63 parental cell line. D. Sarcospheres isolated from 
MG-63 cell line after 7days in non-adherent conditions. (Original magnification: 200x) 
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3.1.2. Expression of pluripotency markers in human OS CSCs 
Oct4 and Nanog are embryonic stem-cell specific transcription factors that play a role in the 
maintenance of self-renewal and pluripotency of stem cells and has been found to be up-
regulated in CSCs. Confocal immunofluorescence analysis revealed the expression of Oct4 
and Nanog in CSCs subpopulations localized both in the nuclei and the cytoplasm but none 
of the pluripotency-associated markers were detected in MNNG/HOS or MG-63 parental 
cells. 
 
Figure 3.2. Representative confocal microscopy images of immunofluorescence staining for pluripotency 
markers Oct4 and Nanog in (A) MNNG/HOS and derived CSCs and (B) MG-63 and derived CSCs. Cells were 
counter-stained with Hoechst 33342 to identify cell nuclei. Arrows indicate the expression of Oct4 and 
Nanog in CSCs localized in the nuclei and in the cytoplasm. (Magnification 400x) 
 
3.2. Effects of METF on cell viability and proliferation of OS cells 
3.2.1. Effects of METF on cell viability of OS cells 
Before starting the studies of co-administration of METF with DOX, we analyzed the effects 
of METF by itself in cells viability and proliferation, using the MTT and BrdU assays, 
respectively. This study was performed after 48h incubation with 0.05mM, 0.1mM, 1mM, 
2mM and 5mM of METF. 
METF induced a progressive decrease in cell viability of both MNNG/HOS and MG-63 
parental cells and corresponding CSCs, although the effects are more pronounced for CSCs as 
depicted in Figure 3.3 and Table 3.1.  
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For concentrations above 1 mM (for MG-63 cells) or 2 mM (for MNNG/HOS cells) the 
percentage of viable CSCs is significantly lower (p<0.05) when compared with that in 
corresponding parental cells exposed to equal concentrations of METF.  
The MG-63 cell line is less susceptible to METF-inducing cytotoxicity compared with 
MNNG/HOS cells. For MNNG/HOS cells, the reduction in cell viability was more pronounced 
(Figure 3.3 A, Table 3.1) and was significant for concentrations starting from 0.1mM, whereas 
for the MG-63 the effect on cell viability was inferior and only significant for concentrations 
above 1 mM (Figure 3.3 B, Table 3.1).  
 
 
 
 
 
 
Figure 3.3. Percentage of viable cells after treatment with different concentrations of METF (0.05-5mM), 
for MNNG/HOS cells and CSCs (A) and MG-63 cells and CSCs (B). These results were presented as mean ± 
standard deviation (SD) from three independent assays (n=3) performed in triplicate.  
*p<0.05 when compared with corresponding control cells (untreated) 
†p<0.05 when compared with corresponding parental cell line, in the same conditions 
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Table 3.1. Effect of METF on cell viability of parental MNNG/HOS and MG-63 cells and corresponding 
CSCs. 
Abbreviations: METF, metformin. Cells were incubated with increasing concentrations of METF (0.05-5mM) 
for 48 hours. Cytotoxicity was evaluated using the MTT colorimetric assay. Results are expressed as mean ± 
standard deviation (SD) of at least three independent experiments performed in triplicate. 
*p<0.05 when compared with control cells (untreated) 
†p<0.05 when compared with corresponding parental cell line, in the same conditions 
 
3.2.2. Effects of METF on cell proliferation of OS cells 
To investigate the effects of METF on cell proliferation we performed a BrdU incorporation 
assay. METF at low concentrations of 0.05 mM and 0.1 mM (within the range of the 
recommended therapeutic doses) did not reduced significantly cell proliferation neither of 
parental cells nor of corresponding CSCs populations, as depicted in Figure 3.4 and Table 3.2. 
Significant anti-proliferative effects of METF were observed for concentrations equal or 
above 1 mM in both parental and CSCs.  
From the two CSCs populations, the one obtained from the MNNG/HOS cell line appears to 
be more susceptible to the anti-proliferative effect of METF, as indicated by the lower 
percentage of actively proliferative cells comparatively to MG-63-derived CSCs exposed to 
the same concentrations of METF (Figure 3.4 and Table 3.2). 
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Figure 3.4. Percentage of proliferative cells after treatment with different concentrations of METF (0.05-
5mM), for MNNG/HOS cell line and corresponding CSCs (A) and MG-63 cell line and corresponding CSCs (B). 
These results were presented as mean ± standard deviation (SD) from three independent assays (n=3) 
performed in triplicate for parental cell lines and in duplicate for CSCs. 
*p<0.05 when compared with untreated parental cells 
†p<0.05 when compared with corresponding parental cell line, in the same conditions 
 
 
Table 3.2.Effect of METF on cell proliferation of parental MNNG/HOS and MG-63 cells and corresponding 
CSCs. 
Abbreviations: METF, metformin. Cells were incubated with increasing concentrations of METF (0.05-5mM) 
for 48 hours. Cytotoxicity was evaluated using the BrdU incorporation assay. Results are expressed as mean 
± standard deviation (SD) of three (n=3) independent assays performed in triplicate for parental cells and in 
duplicate for CSCs. 
*p<0.05 when compared with parental cell line (untreated) 
†p<0.05 when compared with corresponding parental cell line, in the same conditions 
 
 
3.3. Sensitivity of parental OS cell lines and CSCs to DOX  
The cytotoxic effects of DOX, the main chemotherapeutic drug used in the treatment of OS, 
were evaluated in both parental MNNG/HOS and MG-63 cells and in corresponding CSCs. Cell 
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viability was assessed using the MTT colorimetric assay after 48h incubation with increasing 
concentrations of DOX (0.001-100µM).  
The individual dose-response curves obtained and corresponding IC50 values are 
represented in Figure 3.5 and Table 3.3, respectively. 
The treatment with DOX induced a decrease in cell viability in both parental MNNG/HOS 
and MG-63 cells and corresponding CSCs, in a dose-dependent manner. However, this effect 
was less marked for the CSCs compared to parental cells, as depicted in the dose-response 
curve of CSCs that is shifted to the right side; indicating that CSCs need a higher concentration 
of DOX to accomplish the same cytotoxic effect observed in corresponding parental cells. 
 
 
 
 
 
 
 
Figure 3.5. Representative dose-response curves for DOX in MNNG/HOS/CSCs (A) and MG-63/CSCs (B) fitted 
to a sigmoidal function. 
 
 
The mean IC50 value for CSCs isolated from the MNNG/HOS cell lines was 1.96 ± 1.00 µM, 
significantly higher (p<0.05) than that estimated for parental cells (0.64 ± 0.19 µM) (Table 
3.3). Regarding the MG-63 cell line, the IC50 values obtained for CSCs (1.97 ± 0.11 µM) was 
higher although not statistically significant as compared with that in parental cells (1.39 ± 
0.25 µM) (Table 3.3). 
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Table 3.3. IC50 values of DOX in parental cell lines, MNNG/HOS and MG-63, and in corresponding CSCs. 
 
Abbreviations: IC50, half maximal inhibitory concentration; DOX, doxorubicin. Cells were incubated with 
increasing concentrations of DOX (0-100µM) during 48 hours. Cytotoxic effect was evaluated using the MTT 
colorimetric assay. The IC50 values were obtained from a sigmoidal fitting of the dose-response curves. 
Results are expressed as mean ± standard deviation (SD) of at least three independent assays performed in 
triplicate. 
*p< 0.05 when compared with MNNG/HOS cells. 
 
3.4. Effect of METF on DOX-induced cytotoxicity in parental cells and 
CSCs 
Based on our previous observations that CSCs are more susceptible to METF than their 
differentiated counterparts, as indicated by the MTT and BrdU assays, we attempt to analyze 
the chemosensitizer effects of METF when administered in combination with DOX (a standard 
chemotherapeutic drug for OS) in what concerns cell viability. To further identify any 
potential synergy or additivity between DOX and METF we used different drug combinations. 
DOX was tested at three different concentrations equal, below and above the IC50 of parental 
cells (0.25 µM; 0.5 µM and 1 µM). Each of these DOX concentrations was combined with 0.05 
mM, 0.1 mM, 1 mM, 2 mM and 5 mM of METF. 
The effects of METF in combination with DOX on cell viability of MNNG/HOS and derived 
CSCs are presented in Figure 3.6 and Table 3.4. A chemosensitizing effect of METF was mainly 
observed when co-administered with the lowest tested concentration of DOX (0.25 µM), 
which by itself induced a slight decrease in cell viability to 78.41 ± 5.92 % in MNNG/HOS cells 
and of 92.42 ± 10.35 % in CSCs. The combination with METF increased the susceptibility of 
both parental MNNG/HOS and CSCs to DOX, as evidenced by the lower percentage of viable 
cells that decreased significantly in relation to the control (treated cells with 0.25 µM). This 
effect, in parental MNNG/HOS cells, was not very pronounced (although significant) and was 
maintained almost constant within the range of METF concentrations between 0.05 mM and 
2 mM.  For 5 mM of METF cell viability decreased to 34.82 ± 4.71 % which correspond to 
 IC50 (µM) 
 MNNG/HOS CSCs MG-63 CSCs 
DOX 0.64 ± 0.19 (n=6) 1.96 ± 1.00* (n=6) 1.39 ± 0.25 (n=3) 1.97 ± 0.11 (n=3) 
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relative percentage variation of 55.6 %. For concentrations of DOX of 0.5 µM or 1 µM, the 
chemosensitizing effects of METF were not significant except when used at 5 mM. 
In CSCs, the chemosensitizing effect was also more evident when combined with 0.25 µM 
DOX. The decrease on cell viability was more pronounced and occurred in a dose-dependent 
manner (Figure 3.6 and Table 3.4). A dose of 2 mM or 5 mM of METF combined with 0.25 µM 
DOX decrease the percentage of viable CSCs to 63.07 ± 12.69 % and 9.38 ± 6.35 %, 
respectively, which corresponds to a relative percentage variation with respect to treated 
cells with 0.25 µM DOX of 31.7 % and 89.9 %, respectively. The same combination of drugs in 
MNNG/HOS cells resulted in a smaller relative percentage variation of 12.5 % and of 55.6 % 
(Table 3.4). When combined with higher concentrations of DOX, the chemosensitizing effect 
of METF was significant when used at the highest concentrations (2 mM and 5 mM). 
The combination index (CI) obtained by using dose-response curves for each drug alone or 
in combination varied between 0.49 and 0.60 for METF concentrations inferior to 1 mM, 
indicating a strong to moderate synergistic effect. For METF concentrations equal or above 1 
mM the CI emerge in the range of 0.85 and 0.95 indicating an addictive effect.  
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Percentage of viable cells after 48h of treatment with DOX (0.25µM, 0.5µM and 1 µM) in 
combination with different concentrations of METF (0.05mM-5mM) as assessed by the MTT assay in 
MNNG/HOS (A) and CSCs (B). The results were presented as mean ± standard deviation (SD) from three 
independent assays (n=3) performed in triplicate. 
*p<0.05 when compared with control (treatment of DOX alone) 
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Table 3.4. Effects of METF on cytotoxicity of DOX in MNNG/HOS and CSCs. 
Abbreviations: METF, metformin; CSCs, Cancer Stem Cells; RPV, Relative Percentage Variation. Cells were 
incubated with DOX (0.25-1.0µM) in combination with increasing concentrations of METF (0-5mM) for 48 
hours. Cytotoxicity was evaluated using the MTT colorimetric assay. Results are expressed as mean ± 
standard deviation (SD) of four (n=4; 0.05 and 0.1mM of METF in MNNG/HOS) and three (n=3) independent 
assays performed in triplicate. 
*p<0.05 when compared with parental cell line (treatment of DOX alone) 
The relative percentage variation (RPV) was calculated by dividing the difference on cell viability between 
DOX and DOX-METF treated cells by the viability of DOX treated cells. 
 
 
The results obtained with the MG-63 cell line were similar to those observed with the 
MNNG/HOS cells. METF exerted a small chemosensitizing effect in cells treated with 0.25 µM 
DOX. The cytotoxic response of MG-63 cells to 0.5 µM or 1 µM of DOX was not significantly 
altered when administered in combination with METF, (except when administered at 5 mM) 
as indicated in Figure 3.7A and Table 3.5. 
As shown in Figure 3.7B, a dose-dependent effect was observed in the viability of CSCs 
treated with DOX in combination with increasing concentrations of METF. This effect was 
abrupt and significant for a METF concentration equal or above 1 mM and was observed for 
all DOX concentrations tested, being the strongest effects achieved with 5 mM of METF 
(Figure 3.7B, Table 3.). 
The CI values obtained from the Compusyn software identify a synergism between DOX and 
METF at concentrations between 0.05 and 1mM, with CI values between 0.62 and 0.85. For 
METF concentrations above 1 mM the CI values emerge in a range of 0.9 to 0.95 identifying 
an additive effect. 
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Figure 3.7. Percentage of viable cells after 48h of treatment with DOX (0.25µM, 0.5µM and 1 µM) in 
combination with different concentrations of METF (0.05mM-5mM) assessed by the MTT colorimetric assay 
in MG-63 (A) and CSCs (B). These results were presented as mean ± standard deviation (SD) from three 
independent assays (n=3) performed in triplicate.  
*p<0.05 when compared with control (treatment of DOX alone) 
 
 
Table 3.5. Effects of METF on cytotoxicity of DOX in MG-63 and CSCs. 
 
Abbreviation: METF, metformin; CSCs, Cancer Stem Cells; RPV, Relative Percentage Variation. Cells were 
incubated with DOX (0.25-1.0µM) in combination with increasing concentrations of METF (0.05-5mM) for 
48 hours. Cytotoxicity was evaluated using the MTT colorimetric assay. These results were presented as 
mean ± standard deviation (SD) from three independent assays (n=3) performed in triplicate. 
*p<0.05 when compared with parental cell line (treatment with DOX alone). 
The relative percentage variation (RPV) was calculated by dividing the difference on cell viability between 
DOX and DOX-METF treated cells by the viability of DOX treated cells. 
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3.5. Effect of METF on sphere-formation and self-renewal of CSCs 
After verifying that CSCs are more susceptible to METF than parental cells, next we 
evaluated the effect of different concentrations of METF on sphere formation and self-
renewal ability of CSCs, by conducting a sphere forming assay, using monolayer parental cells 
and dissociated cells from first generation spheres, respectively. We found that METF within 
the range of concentrations tested did not induce significant alterations on the sphere 
forming efficiency of MNNG/HOS cells as represented in the graph of Figure 3.8 A. However, 
as shown in the images of Figure 3.8 A, the size of the spheres formed at higher 
concentrations of METF (2mM and 5mM) were smaller and less compact compared with 
untreated cells. Regarding self-renewal ability, we observed that METF at 2 mM and 5 mM 
decreased significantly the number of secondary sarcospheres compared with untreated 
cells, as depicted in Figure 3.8 B. For 1 mM of METF the formed spheres are smaller and for 
2 mM and 5 mM, revealed morphology more likely to be cellular aggregates with irregular 
contours and not real spheres as observed in controls or cells treated with low concentrations 
of METF, as shown in Figure 3.8 B. 
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Figure 3.8. Effects of METF on sphere formation and self-renewal ability of MNNG/HOS cells. (A) 
Morphological appearance and sphere-forming efficiency of MNNG/HOS cells treated with METF at 
indicated concentrations. (B) Self-renewal ability of primary generation sarcospheres in the presence of 
METF. These results were presented as mean ± standard error of the mean (SEM) from three independent 
assays (n=3). 
*p<0.05 when compared with parental cells (untreated) 
 
The results obtained with the MG-63 cells were similar to those obtained with the 
MNNG/HOS cell line. METF decreased the sphere-forming efficiency in both primary and 
secondary sarcospheres for concentrations of 2mM or 5mM of METF. Likewise, the size of 
spheres was smaller than those formed in medium without METF. With the increasing 
concentrations of METF, the sizes of the spheres decreased and start losing the appearance 
of round colonies acquiring a morphology of cellular aggregates mainly for the highest 
concentrations as shown in the Figure 3.9 A and B. 
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Figure 3.9. Effects of METF on sphere formation and self-renewal ability of MG-63 cells. (A) Morphological 
appearance and sphere-forming efficiency of MG-63 cells treated with METF at indicated concentrations. 
(B) Self-renewal ability of primary generation sarcospheres in the presence of METF. These results were 
presented as mean ± standard error of the mean (SEM) from three independent assays (n=3). 
*p<0.05 when compared with parental cells (untreated) 
 
 
 
3.6. Activation of sensors of energetic status of the cell by METF in 
parental cells and corresponding CSCs 
3.6.1.  Expression of activated AMPK in parental cells and corresponding CSCs 
The main mechanism of anti-neoplastic action by METF has been attributed to the 
activation of AMPK, which is a cellular energy sensor involved in regulating cellular 
metabolism and proliferation. Once activated, METF downregulates energy consuming 
processes (e.g. protein synthesis and proliferation) and upregulates processes that lead to 
ATP synthesis (e.g. glucose uptake). Based on this assumption we evaluated the expression 
levels of the activated form of AMPK in both parental cells and corresponding derived CSCs 
after 48h cells exposure to METF over a range of concentrations between 0.05 mM to 2 mM. 
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It was not possible to test the effects of 5mM METF because of the very small amount of 
protein obtained.  
Western blot analysis showed a progressive increase in AMPK-α phosphorylation levels 
(pAMPK) with increasing concentrations of METF, in both parental MNNG/HOS and MG-63 
cells and corresponding CSCs, becoming significant for 2 mM, whereas the total AMPK 
remained almost unchanged as indicated in Figures 3.10 and 3.11. Nevertheless, METF-
induced AMPK activation appeared most pronounced in both CSCs populations as compared 
to respective parental cells (Figures 3.10B and 3.11B), further suggesting that CSCs are more 
sensitive than parental cells to METF-induced AMPK activation. 
 
 
 
 
 
 
Figure 3.10. Representative Western Blot analysis of pAMPK expression levels in MNNG/HOS (A) and 
corresponding CSCs (B) after incubation with increasing concentrations of METF during 48 hours. The graphs 
below show the quantitative analysis of pAMPK levels normalized to the total AMPK and expressed as a 
ratio of the levels found in untreated cells (control). These results were presented as mean ± standard error 
of the mean (SEM) from four independent assays (n=4). 
*p<0.05 when compared with control (untreated) 
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Figure 3.11. Representative Western Blot analysis of pAMPK expression levels in MG-63 (A) and 
corresponding CSCs (B) after incubation with increasing concentrations of METF during 48 hours. The graphs 
below show the quantitative analysis of pAMPK levels normalized to the total AMPK and expressed as a 
ratio of the levels found in untreated cells (control). These results were presented as mean ± standard error 
of the mean (SEM) from five and four independent assays, respectively (n=5 for MG-63 and n=4 for CSCs). 
*p<0.05 when compared with control (untreated) 
 
3.6.2.  Expression of the downstream target (mTOR) of activated AMPK in 
parental cells and corresponding CSCs 
The suppression of mTOR activity through AMPK activation is believed to constitute the 
major mechanism underlying the anti-cancer activities of METF. Therefore we evaluated the 
expression levels of mTOR following exposure to METF verify whether AMPK activation 
induce a concomitant mTOR inhibition. This analysis was performed by Western blot only 
once and the results are presented in Figure 3.12 and 3.13. 
The expression levels of mTOR in parental MNNG/HOS treated with 0.1mM or 1mM of 
METF increased 2-3 fold, in relation to untreated cells, but remained almost constant for the 
other METF tested concentrations (Figure 3.12 A). In corresponding CSCs, the mTOR 
expression levels decreased to less than half in relation to the control and remained almost 
constant irrespective of the METF concentrations as depicted in Figure 3.12 B.  
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Figure 3.12. Representative Western Blot analysis of mTOR expression levels in MNNG/HOS (A) and 
corresponding CSCs (B) after incubation with increasing concentrations of METF during 48 hours. The 
graphs show the quantitative analysis of mTOR levels normalized to β Actin and expressed as a ratio of 
the levels found in untreated cells (control) (n=1).  
 
The expression levels of mTOR in parental cell line MG-63 decreased slightly for treatments 
with 0.05 mM or 0.1 mM of METF and increased at concentrations of 1 mM or 2 mM as 
demonstrated in Figure 3.13 A. In the case of MG-63-derived CSCs there were no significant 
changes in the expression levels of mTOR expression, with the treatment of METF, suggesting 
they are more resilient to the effect of METF in the reduction of mTOR levels, compared with 
MNNG/HOS-derived CSCs. 
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Figure 3.13. Representative Western Blot analysis of mTOR expression levels in MG-63 (A) and 
corresponding CSCs (B) after incubation with increasing concentrations of METF during 48 hours. The graphs 
below show the quantitative analysis of mTOR levels normalized to β Actin and expressed as a ratio of the 
levels found in untreated cells (control) (n=1).  
 
3.7.  Effects of METF on metabolic activity of parental cells and CSCs 
One of the effects of METF is to upregulate processes that lead to ATP synthesis including 
glucose uptake, secondary to activation of AMPK. Therefore we measure the cellular uptake 
of [18F]FDG, a glucose analogue radiotracer in both parental and CSCs after treatment with 
various concentrations of METF at a maximum of 2 mM. Is was not possible to test the effects 
of 5mM of METF because of the few number of adherent surviving cells which hindered the 
execution of the assay. 
A progressive and dose-dependent increase in [18F]FDG uptake was observed in both 
parental MNNG/HOS and MG-63 cells, although the effects are more pronounced in 
MNNG/HOS cells as depicted in Figure 3.14 and Table 3.6.  
In MNNG/HOS cells the cellular uptake of [18F]FDG increased 8-fold and 20-fold when 
treated with 1mM or 2 mM of METF, respectively in relation to untreated cells, whereas in 
MG-63 cells the increase was of 1.6 and 2.4-fold under the same conditions. These 
differences on metabolic response to METF between MNNG/HOS and MG-63 cells, can be 
related with other mechanisms regulating [18F]FDG uptake. 
As shown in Figure 3.14, METF had no noticeable effects on the metabolic activity of CSCs, 
since no significant changes were observed in [18F]FDG uptake following treatment with 
METF, suggesting that METF may not overtake the quiescent status of CSCs and consequent 
lower energy requirements. 
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Figure 3.14. Uptake of [18F]FDG after treatment with different concentrations of METF (0.05-2mM), for 
MNNG/HOS cell line and corresponding CSCs (A) and in MG-63 cell line and corresponding CSCs (B). These 
results were presented as mean ± standard error of the mean (SEM) from three independent assays (n=3) 
performed in triplicate for both parental cell lines and corresponding CSCs. 
*p<0.05 when compared with control (untreated)  
 
 
Table 3.6. [18F]FDG Uptake after treatment with different concentrations of METF in both parental cell 
lines (MNNG/HOS and MG-63) and corresponding CSCs. 
 
Abbreviation: METF, metformin; CSCs, Cancer Stem Cells. Cells were incubated with increasing 
concentrations of METF (0-2mM) for 48 hours. Data are displayed relative to respective controls (untreated 
cells). These results were presented as mean ± standard error of the mean (SEM) from three independent 
assays (n=3). 
*p<0.05 when compared with control (untreated) 
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In this study we purpose to evaluate the potential role of METF as co-adjuvant when used 
in combination with DOX in the treatment of OS targeting CSCs that are believed to play a 
critical role in drug resistance and tumor progression.  
METF is a widely used and well tolerated drug prescribed to treat patients with type II 
diabetes. This drug has recently received particular attention for its potential anti-cancer 
properties due to anti-proliferative effects on tumor cells and anti-tumor growth effects in 
mouse xenografts suggesting the possibility of its use as an anticancer agent in non-diabetic 
contexts [84]. We attempt to evaluate the cytotoxicity of METF towards drug-resistant CSCs 
existing in OS, in combination with DOX, which is the main chemotherapeutic agent used in 
the treatment of OS.  
Previous studies performed in our group have demonstrated the presence of a 
subpopulation of cells exhibiting stem-like properties in a human OS cell line (MNNHG/HOS) 
that were relatively resistant to chemotherapeutic drugs (including DOX) and radiotherapy 
as compared to their differentiated counterparts [19]. In this study we have identified a stem-
like cell population in another human OS cell line (MG-63), using the same functional 
approach based on the sphere-forming assay, which is a recognized and currently used 
method for identifying CSCs in solid tumors [36]. Under serum-starvation and anchorage-
independent conditions only cells with stem-like properties can survive forming suspended 
spherical colonies while more differentiated cells are unable to survive in these stressful 
conditions being eliminated. We observed that MG-63 cells likewise MNNG/HOS formed 
spherical colonies for at least four generations under these stressful culture conditions which 
is indicative of their self-renewal ability, a hallmark of CSCs. Furthermore, when transferred 
into adherent flasks with serum containing standard growth medium, CSCs expanded in 
monolayer and generated progeny with the same morphological phenotype of the parental 
cell line, demonstrate their differentiation ability, another CSCs property.  
 
To further confirm the stem-like nature of the isolated CSCs, we analysed the expression of 
Oct4 and Nanog, two core regulatory transcription factors required for maintaining 
pluripotency and self-renewal of embryonic stem cells (ESCs). The immunofluorescence 
staining showed that both Oct4 and Nanog are expressed in CSCs derived from the 
MNNG/HOS and MG-63 cells, and are localized in both the nuclei and the cytoplasm of cells 
while no immunoexpression were found in parental cells. The localization of transcription 
factors in the cytoplasm suggests that they might display other function in CSCs distinct of 
self-renewal regulation. Recent data demonstrated that ESCs-associated proteins are highly 
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expressed in different tumors and contribute to tumor aggressiveness and poor outcome, by 
promoting tumor cell growth, anti-apoptosis and invasiveness, which are the typical 
characteristics associated to CSCs [103], however their exact role are not fully understood. In 
previous work the protein expression levels of Oct4 and Nanog were found highly elevated 
in MNNG/HOS-derived CSCs compared with parental cells as determined by Western blot 
[19]. Other authors in independent studies demonstrated the expression of these markers in 
cancer stem-like cells isolated from bone and soft-tissue sarcomas confirming the higher 
expression of Oct4 and Nanog in sarcospheres than adherent cells [14, 36]. Levings and 
collaborators (2009) through in vivo transplantation demonstrated that a small number of 
cells expressing Oct4 could amplify and increase the expression or activation of Oct4 
representing a >100-fold enrichment of tumorigenic capacity in OS, which represents other 
function of Oct4 than regulatory of pluripotency. This marker was found to be only active in 
TICs and not in the normal MSCs or in the more differentiated osteoblast cell line [105]. 
 
The dose-response studies to DOX confirmed the high resistance profile of the CSCs 
populations to this drug, as indicated by the IC50 values taken from the dose-survival curves 
obtained after 48h incubation with DOX (Figure 3.5 and Table 3.3). 
Regarding CSCs derived from the MNNG/HOS cell line, the IC50 (IC50 = 1.96 ± 1.00 µM) was 
3-fold higher than that observed for parental MNNG/HOS cells (IC50 = 0.64 ± 0.19 µM). 
Relatively to the MG-63 cell line, the IC50 was 1.4-fold higher in CSCs (IC50= 1.97 ± 0.11 µM) 
than in parental cells (IC50 = 1.39 ± 0.25 µM). One mechanism that has been proposed to 
explain the chemoresistance of CSCs is the activity of ABC transporters that mediate drug 
efflux, preventing the cellular accumulation of chemotherapeutic agents. DOX is a transport 
substrate of Pgp and BCRP, two transmembrane efflux transporters that have been found to 
be overexpressed in CSCs of several malignancies, namely breast, hepatocellular, 
gastrointestinal and thyroid cancers [62]. These proteins behave as drug efflux pumps 
preventing the intracellular accumulation of DOX at toxic levels and confer a multidrug 
resistance phenotype and are associated with drug resistance, tumor recurrence and poor 
outcome in OS patients [106, 107]. Previous studies conducted in our lab demonstrated high 
expression levels of Pgp and BCRP in CSCs derived from the MNNG/HOS cell line, which might 
explain the higher resistance of such CSCs to DOX [19]. Additionally, verapamil (VER) co-
administration, a non-specific inhibitor of ABC transporters, sensitized CSCs to DOX and had 
no significant effects on parental cells further suggesting that both transporters are 
functionally active and contribute to DOX resistance of CSCs. Furthermore, studies conducted 
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in our laboratory showed that the increased resistance of MNNG/HOS-derived CSCs to DOX-
inducing apoptosis was related with the disruption of intrinsic or mitochondrial apoptotic 
pathway demonstrated by an upregulation of anti-apoptotic proteins and a downregulation 
of pro-apoptotic proteins in these cells [82]. 
 
Before examining the anticancer properties of METF together with DOX, we first analysed 
the effects of METF by itself on cell viability and proliferation using the MTT and BrdU 
incorporation assays, respectively, in a concentration ranging between 0.05 mM and 5 mM. 
Most of the studies found in the literature use much higher concentrations of METF (typically 
between 5mM and 30 mM) than the recommended doses for clinical use (30-50 nM), since 
in most cases little or no effects on cell proliferation are observed at these low 
concentrations. Our results showed that METF induced a decrease in cell viability and 
proliferation in both parental cells and corresponding CSCs populations, for concentrations 
equal or above 1mM. For lower METF concentrations within the range of clinically 
therapeutic doses, the effects were not significant. However in both cell lines (MNNG/HOS 
or MG-63), the effects of METF either on viability or proliferation were more pronounced in 
the CSCs populations. These results are in accordance with those reported in studies 
performed in thyroid and pancreatic CSCs. In these studies it was observed a decrease in cell 
proliferation follow METF treatment [88, 94]. Another study performed in breast CSCs show 
that METF was preferentially cytotoxic to CSCs relatively to non-CSCs, however the 
mechanism underlying this effect is not well understood yet [108]. 
 
The potential benefits of METF as an anticancer agent are believed to be mediated by the 
activation of AMPK which plays a major role in the regulation of energetic metabolism and 
proliferation in tumor cells. This drug activates the AMPK pathway because of the inhibition 
of mitochondrial complex I. This alteration in mitochondria activity causes an alteration in 
AMP/ATP ratio that results in AMPK activation, which in turn suppresses the activity of mTOR, 
a signaling pathway clinically relevant to cancer that plays a central role in regulating cell 
growth by controlling mRNA translation and ribosome biogenesis. The activated form of 
AMPK inhibits the mTOR activity via phosphorylation and stabilization of the tumor 
suppressor TSC2 a subunit of the TSC2/TSC1 complex that negatively regulates mTOR 
signaling or through direct phosphorylation of co-signaling molecules that bind to mTOR and 
inhibit its action [85]. 
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We examined the expression levels of phosphorylated AMPK to further verify if the 
activation of AMPK is responsible for the effects of METF observed in OS cells, and in fact we 
observed an increase in AMPK phosphorylation in both parental MNNG/HOS and MG-63 cell 
lines as well as in the corresponding subpopulations of CSCs in a dose-dependent manner. 
However the AMPK activation appears to be more pronounced in CSCs than in their 
counterparts suggesting that CSCs are more sensitive to METF-induced AMPK activation. 
Contrary to what is described in the literature we did not observe a significant concomitant 
decrease in mTOR expression in any of the cell lines tested, further suggesting that METF at 
the tested concentrations reduces cell proliferation through an independent mechanism of 
mTOR activity. However, the measurement of the expression levels of mTOR was only 
performed one time, and should be confirmed through repeated experiments. 
The anticancer effects of METF has been evaluated in several types of cancer, namely 
endometrial, breast, pancreatic and lymphoma and it was shown to be related with AMPK 
activation and subsequent mTOR inhibition. In endometrial cell lines mTOR inhibition leads 
to suppression of proliferation through cell cycle arrest, whereas in breast cancer cell lines, 
the decrease in cell growth was due to the inhibition of mTOR and to a decrease in 
phosphorylation of its downstream targets with a reduction in translation initiation [87, 92].  
We cannot exclude other effects of METF independent of AMPK activation can afford the 
results observed in our study. Sahra et al. (2008) show that METF exerts an antiproliferative 
effect in prostate cell lines trough cell cycle arrest in G0/G1 phase which is correlated with a 
decrease in the expression of cyclin D1, E2F1 and phosphorylation of pRb. Furthermore, these 
effects were accompanied by a downregulation of the mTOR pathway but independently of 
AMPK activation, since the inhibition of AMPK did not prevent the G0/G1 cell cycle arrest 
induced by METF [89]. Moreover, studies performed by Memmott et al. (2010) in lung cancer 
support the hypothesis that METF decrease cancer cell proliferation by decreased 
phosphorylation of IGF-1R and decrease levels of circulating IGF-1 and insulin [95]. 
Furthermore, in thyroid cancer cells were shown that METF could inhibits insulin/IGF 
signaling apart from AMPK/mTOR pathway [94]. 
 
Cancer cells preferentially use glycolysis to generate energy, releasing lactate from the cell 
despite the abundance of oxygen, in a phenomenon referred to as “the Warburg effect” 
[111]. As already mentioned, the AMPK complex functions as a metabolic checkpoint which 
regulates the cellular response to energy availability. During periods of energetic stress, 
AMPK becomes activated in response to an increased AMP/ATP ratio and is responsible for 
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shifting cells towards a more oxidative metabolic phenotype [112]. The activation of AMPK 
downregulates many of the energy-consuming activities of cells, including protein synthesis 
and cellular proliferation; also up-regulates pathways for energy production, such as 
glycolysis and fatty acid oxidation, and induce externalization of glucose transporters. 
To further evaluate if METF induces differential effects in metabolic status between 
parental and CSCs, we measure the cellular uptake of [18F]FDG following exposure to METF. 
[18F]FDG is a glucose analogue used in the clinical practice in PET imaging studies to detect 
malignant tumors [113]. This radiotracer accumulates preferentially in tumor cells due to 
their high metabolic activity and energy requirements and is considered a good indicator of 
the metabolic status of tumor cells. The increased accumulation of [18F]FDG in tumor cells in 
relation to non-tumor cells is attributed to an increase in the activity of enzymes that 
regulates glucose metabolism, such as hexokinase, and also due to the overexpression of 
glucose transporter proteins, such as GLUT-1 and GLUT-3 in tumor cells [97]. Our results 
showed that METF induced a progressive and dose-dependent increase in [18F]FDG uptake in 
parental cells but not in CSCs that exhibited a constant [18F]FDG uptake along the METF 
concentrations tested (Figure 3.14) . 
We know from previous studies that CSCs are less glycolytic than differentiated OS cells, 
probably related with their quiescent status and consequent low energy requirements, which 
make them less susceptible to the effects of metabolic modulators METF in contrast with 
highly proliferative cells that rely more on glycolysis than on oxidative phosphorylation for 
glucose metabolism [19]. Würth et al. (2013) in a similar study performed in glioblastoma 
cells lines also observed significant differences in [18F]FDG uptake between differentiated 
cells and CSCs in response to METF. CSCs have not responded to [18F]FDG  uptake comparing 
to their glioblastoma cancer cells which increase the [18F]FDG uptake following METF 
treatment [115]. 
 
On the basis of our observations that METF exerted a more selective effect against CSCs, 
we evaluated the effect of METF in sphere forming and self-renewal abilities of both 
subpopulations of CSCs. We found that METF at higher concentrations (2 mM and 5 mM) 
impaired the sphere forming efficiency and reduced the sphere size of both primary and 
secondary sarcospheres, which reflects suppression of self-renewal and proliferation of CSCs. 
These results are in accordance with those reported by Bao et al. (2011) in CSCs isolated from 
pancreatic cancer cells. In addition to a decrease in proliferation of CSCs, they observed that 
METF decreased the sphere forming ability of CSCs by lowering the expression of CSCs marker 
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genes, such as CD44, EpCAM, Nanog and Oct4 [88]. A reduction in sphere formation and 
sphere size was equally observed in thyroid carcinoma CSCs at similar doses of METF [94]. 
Taken together these results suggest that METF modulates CSCs-specific genes linked with 
self-renewal capacity of cancer stem-like cells. 
The Wnt/β-catenin is a developmental signaling pathway involved in the maintenance of 
the self-renewal capacity of stem/progenitor cells through the inhibition of terminal 
differentiation. This signaling pathway is deregulated in a variety of cancers and is considered 
an essential pathway in driving CSCs self-renewal and maintenance of their tumorigenic 
phenotype. Recent studies suggest that METF affects osteoblasts differentiation through 
modulation of the Wnt/β-catenin signaling pathway, by reducing the protein levels of β-
catenin, which is the downstream effector of canonical Wnt signaling in osteoblast like-cells.  
Takatani et al. (2011) showed that activation of AMPK by METF suppresses the 
transcriptional activity of the Wnt/β-catenin signaling pathway in an OS cell line by promoting 
the phosphorylation of β-catenin and its consequent degradation, further suggesting a cross-
talk between AMPK and Wnt/β-catenin signaling [100]. 
Unpublished data obtained in our lab revealed a strong nuclear accumulation of β-catenin 
(the hallmark of active canonical Wnt signaling pathway) in CSCs-enriched cell populations 
isolated from the OS cell lines that we used in this study (MNNG/HOS and MG-63), while 
parental cells displayed only a membranous staining pattern, suggesting that Wnt/β-catenin 
signaling is required for the maintenance of CSCs. This information together with interplay 
between AMPK and the Wnt/β-catenin signaling pathway suggests that METF might impair 
the self-renewal capacity of CSCs through AMPK-mediated inhibition of the canonical Wnt 
signaling pathway. 
 
Taking in consideration the previous observations that CSCs are more susceptible to METF 
but more resistant to DOX treatment, we attempted to analyse the chemosensitizer effect of 
METF when combined with DOX at cytostatic (below IC50) and cytotoxic (above IC50) 
concentrations.  In fact, by the MTT assay we observed that METF potentiated the cytotoxic 
effects of DOX in both parental and CSCs populations, but with a more pronounced effect on 
CSCs. This chemosensitizing effect of METF was more effective when combined with a 
cytostatic concentration of DOX (below the IC50), that per se exerted a low cytotoxicity against 
resistant CSCs, and was dose-dependent, being synergistic for relatively lower doses of METF 
(< 1mM) and additive for doses equal or above 1 mM. Moreover, the chemosensitizing effect 
of METF did not increased substantially when combined with higher concentrations of DOX, 
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suggesting that METF is effective in combination with reduced dosages of DOX and 
presumably other standard chemotherapeutic drugs. 
METF has been shown to potentiate the cytotoxic action of some chemotherapeutic agents 
including DOX. Iliopoulos et al. (2011) and Hirsch et al. (2009) showed that administration of 
METF together with a reduced dosage of DOX is highly effective in blocking tumor growth 
and preventing relapse in a variety of cancer cell types. Furthermore, they observed that 
combination of METF with higher concentrations of DOX did not translate into an additional 
decrease in cell viability. Thus, METF appears to increase the effectiveness of standard 
chemotherapy and lowering the cytotoxic side-effects associated with chemotherapy in the 
clinical context [99,101].  
Our results demonstrating a preferential cytotoxicity of METF against CSCs in OS, either 
alone or in combination with DOX are exciting and looks promising in the treatment of OS. 
However given the diversity of molecular targets and mechanisms of METF action, further 
studies are needed for a better understanding and elucidation of the molecular mechanisms 
underlying the preferential cytotoxicity of METF against CSCs in OS. 
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In this study we purpose to explore the anticancer properties of METF as co-adjuvant of 
DOX in the treatment of OS targeting CSCs. Our results demonstrated that both OS cell lines 
contain a subpopulation of cells exhibiting stem-like features that can be isolated through the 
sphere formation assay. 
 
The CSCs subpopulations are relatively more resistant to DOX than their differentiated 
adherent counterparts. 
MEFT demonstrated a preferential cytotoxicity against CSCs relatively to corresponding 
parental cells through inhibition of cell viability and proliferation. 
Treatment with METF resulted in activation of AMPK in both cell populations and interferes 
with glucose metabolism in proliferating parental cells, but not in CSCs. 
 
METF potentiates the cytotoxic effects of low doses DOX (below the IC50) preferentially in 
CSCs. 
In conclusion, our results suggest that METF combined with DOX may be an effective 
treatment strategy for targeting CSCs in OS, however more studies are needed to clarify the 
mechanisms underlying the chemosensitizing effects of METF in this particular malignancy 
 
These results suggest that METF can contribute for the treatment of OS CSCs, as co-adjuvant 
of DOX or acting alone, directly in CSCs. However, the mechanism of action of this drug is 
complex; thus, to have a complementary knowledge about METF’s action on OS tumors and 
CSCs a more extensive research is needed. 
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